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ABSTRACT 
 
 
 Ovarian cancer is 6th most common cancer in women worldwide.  It has been 
suggested that incessant ovulation and gonadotrophin stimulation may play a role in 
development of ovarian cancer.  Ovarian cancer carries highest mortality among all 
gynaecological cancers because the early stages are asymptomatic.  The tumour is 
diagnosed only in late stages (Stage III and IV).  No effective screening methods are 
available as in cervical cancer.  Epidemiological evidence suggests that steroid 
hormones (estrogen and progesterone) and amplification of Human epidermal 
growth factior-2 (HER-2/neu) gene are implicated in ovarian carcinogenesis.  Thus 
the steroid hormone receptor positivity on the ovarian surface epithelium and ovarian 
carcinoma is of paramount significance for hormonal therapy.  This study is 
undertaken to review the incidence of ovarian neoplasm in our institution. 
 A total of 132 cases were evaluated in concordance with clinical history, 
histopathological features.  Immunohistochemistry (ER, PR) was done for surface 
epithelial carcinomas.  HER-2/neu expression was compared between malignant 
surface epithelial carcinomas and borderline tumours. 
 Ovarian malignancy (4.1%) was found to be the second most common 
malignancy in female genital tract next to cervical malignancy.  In our institution 
surface epithelial tumour (68.9%) was the most common neoplasm.  Mucinous 
cystadenoma was the commonest tumour. 
 Positive ER(36.3%) and PR(45.4%) expression in surface epithelial 
malignancies proves the mitogenic role of estrogen and progesterone.  HER-2/neu 
showed positive expression in surface epithelial malignancies only (60% serous and 
33.3% of mucinous carcinomas). Negative expression was seen in                        
borderline tumours.  Hence HER-2/neu helps in differentiating borderline and 
malignant tumours.   
 Thus a panel of markers will be helpful in prognostication of ovarian tumours 
and development of targeted therapy.   
KEY WORDS: 
 Ovarian cancer 
 Surface epithelial tumours 
 ER, PR 
 HER-2/neu 
ABBREVIATIONS 
 ER  - Estrogen receptor 
 PR  - Progesterone receptor 
 HER-2/neu - Human epidermal growth factor 
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INTRODUCTION 
 
 Ovarian cancer is the 6
th
 most common cancer in women worldwide. It is the                    
5
th
 leading cause of death among women in the developed countries
1,2
. The incidence rate is 
higher in white women followed by Hispanic, Asians, Black and American Indian women
3
. 
 In India, the Age Standardized incidence Rate (ASR) for ovarian Carcinoma varied 
from 0.9 to 8.4 per 1,00,000 person/year. Studies revealed that the peak incidence is in 
between the age of 55-64 years. The mean annual percentage increase in ASR ranges from 
0.7 to 2.4%
4
.  
The risk factors associated with ovarian tumours  are
5
 
1) Age      4) Hormonal influences   
2) Positive family history   5) Reproductive factors. 
3) Genetic factors  
It has been suggested that incessant ovulation and gonadotrophin stimulation may 
play a role in development of ovarian cancer
6
. Predominantly ovarian neoplasms are sporadic 
in nature. About 5-10% of ovarian cancers are hereditary. These women have inherited 
mutations in BRCA-1 and BRCA-2, tumour suppressor genes
5,7
. 
 For diagnosis of early ovarian cancer, abdominal USG and serum CA-125 were used 
as screening methods.  FNAC can be used to differentiate benign from malignant ovarian 
tumour with an accuracy of 90-95%
8
.  Despite these screening methods, ovarian neoplasm 
carries the highest mortality among all the gynaecological cancers.   This is due to the fact 
that, the early stages are asymptomatic.  The tumour is diagnosed only in late stages                 
(stage III & IV).  No effective screening methods are available as in cervical cancer. 
 5 year survival rate is around 40%.  In late stages it is only 10-20%. The above 
scenario is due to paucity of knowledge about exact etiological factors
9
.  Histological grading 
is an important prognostic factor in the surface epithelial stromal tumours.  Also sub-typing 
11 
 
of surface epithelial stromal tumours into Benign, Borderline and Malignant has important 
influence on therapeutic and prognostic point of view. 
 Following introduction of CA125 in 1981 as biomarker, for epithelial  ovarian 
carcinoma, numerous biomarkers have been emerging substantially
10
. Epidemiological 
evidence suggests that steroid hormones (estrogen and progesterone) and amplification of 
human epidermal growth factor-2 (Her-2/neu) gene are implicated in ovarian 
carcinogenesis
1,2
.  Limited number of clinical trails have demonstrated efficacies of anti 
estrogen and progesterone alone or in combination with chemotherapeutic drugs in the 
treatment course
1
. 
  
 Thus the steroid hormone receptor positivity on the ovarian surface epithelium and 
ovarian carcinoma is of paramount significance for hormonal therapy.  The above strategy 
paves way for novel therapies in the prevention and treatment of ovarian carcinoma
11
. 
 This study is undertaken to review the incidence of ovarian neoplasms in our 
institution.  This study is done with reference to age, histopathological, clinicopathological, 
immunohistochemical  features in concordance with review of journals and various research 
publications. 
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AIM OF STUDY 
1)  To study the incidence of ovarian neoplasms in our institution along with clinical 
correlation.   
2) To study and compare the incidence of malignant ovarian tumour with other female 
genital tract malignancies in our institution. 
3) To study the expression of ER, PR, Her-2/neu amplification status in primary surface 
epithelial tumour malignancies. 
4) To evaluate Her-2/neu expression in distinguishing borderline and malignant surface 
epithelial tumours of ovary. 
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MATERIALS AND METHODS 
 
 This study is a retrospective study carried out in Department of Pathology, Thanjavur 
Medical College from January 2013 to May 2015.  A total of 132 cases of ovarian neoplasms 
referred from Raja Mirasudhar Government Hospital (RMH) were included in this study. 
 The gross specimens were fixed in 10% neutral buffered formalin and processed 
routinely.  Clinical history of the patient including the age, examination findings, radiological 
investigation, USG, CT and FNAC reports were evaluated in detail. 
 4 to 5 bits including the wall with papillary excrescences were taken for  cystic 
ovarian neoplasms.  3 to 4 bits were taken in solid tumours of size less than 5cms. In 
variegated tumours more than 5cms, one block per 1 cm of the tumour was taken in its 
greatest dimension.  Section of 3 to 4μm were cut and stained with hematoxylin and Eosin 
(Appendix - I). 
 The H&E stained slides were reviewed.  Parameters consisting of age, tumour size, 
stage of the disease (FIGO Staging) and histological typing were done according to WHO 
classification criteria.  Serous carcinoma were graded according to recent two tier grading 
system. 
 The immunohistochemical detection of steroid hormonal status (ER, PR) in surface 
epithelial stromal tumour were conducted.  Also the status of Her-2/neu amplification in 
borderline and malignant tumours were studied. 
ER, PR, Her-2/neu STAINING: 
 Representative 4μm sections were taken from paraffin embedded blocks for Immuno 
histochemistry (IHC).  The procedure was performed according to heat induced epitope 
retrieval method with specific antibodies against ER, PR and Her-2/neu. 
14 
 
 Scoring for ER and PR expression was based on the following criteria.  Proportion of 
cells exhibiting distinct nuclear immunostaining and intensity of staining was taken into 
consideration.   
The results were given as Negative (<10%) and Positive (≥10%)12. 
Her-2/neu positivity was assessed using Ellis and Wolf recommendations
13
. 
SCORE STAINING PATTERN 
  
1+ barley perceptible membrane staining in >10% of cells. 
  
2+ weak to moderate complete membrane, staining present in 
>10% of tumour cells. 
  
3+ strong, complete membrane staining in >10% tumour cells. 
 
RESULTS: 
2+ Equivocal 
  
3+ Positive, cytoplasmic staining was considered non-specific. 
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REVIEW OF LITERATURE 
 
EMBRYOLOGY 
 Around sixth week of intrauterine life, sexual differentiation can be recognized. The 
premature gonad is identified as ovary by absence of testicular differentiation. The above 
process is a passive event. Familial XX gonadal dysgenesis is transmitted as autosomal 
recessive trait. The above fact suggests, autosomal genes are essential for human ovarian 
organogenesis. Around 5
th
 week of gestation, gonadal ridges are formed. There after 
epithelial proliferation and mesenchymal condensation occurs.  
 Primordial germ cells are the first to develop in the wall of yolk sac. These epithelial 
cells proliferate to form primitive sex cords. Then they migrate to gonadal ridges. In the 
surface epithelium there occurs proliferation of second generation of gonadal cortical cords. 
These traverse the mesenchyme. These cords split to enclose a single primitive germ cell to 
form follicular cells. The germ cells form oogonia. The coelomic epithelium encloses the 
developing ovary
14
. 
GROSS ANATOMY 
 Ovaries are paired, almond shaped pelvic organ. They are located one on each side of 
the uterus, close to the pelvic wall. The ovaries are attached to the posterior aspect of broad 
ligament by mesovarium(Fig-1). Each ovary measures 4 to 5cm in length, 1.5 to 2.5cm width 
and 0.5 to 1.5cm thickness. The mature ovary weighs about 5 to 10gms. The postmenopausal 
atrophied ovary weighs about 3 to 6gms.   
 
  
Fig.1. Schematic diagram of female genital tract 
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CUT SURFACE 
 Reveals a thin white, outer cortex and major areas occupied by medulla. During 
reproductive period, fluid filled cystic follicles and bright yellow corpora lutea can be seen
15
. 
 
 
 
VASCULAR SUPPLY: 
 Major blood supply of ovary is from Ovarian arteries.  Ovarian artery is a branch of 
abdominal aorta. It anastomosis with the ovarian branches of internal iliac arteries in the 
mesovarium. 
VENEOUS DRAINAGE:  
The right ovarian vein drains into the inferior vena cava. The left ovarian vein drains into the 
left renal vein. 
LYMPHATICS:   
The lymphatics drain into external iliac and paraaortic nodes
7
. 
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HISTOLOGY:  
The ovary is covered by coelomic epithelium which is continuous with the 
mesothelium of peritoneal cavity. The coelomic epithelium is usually a single layer of 
cuboidal cells, columnar or focally pseudostratified. 
 Underneath the surface epithelium, outer collagenous zone termed Tunica Albugenia 
and inner cellular cortex containing follicles are seen.  The medulla contains stroma and 
hilum. 
 In the cortex lies the primordial follicle which undergoes maturation into primary, 
secondary, tertiary and Graffian follicles, which releases oocyte during ovulation. Fig.2, 3 
The stroma consist of spindle cells exhibiting storiform pattern
7
.  The blood vessels gain 
entrance through hilum.  Hilus cells contain crystals of Reinke. 
 
 
 
 
 
 
 
 
 
 
FUNCTIONS 
 Ovaries produce ova and hormones under the feedback control mechanisms of 
hypothalamo-pituitary ovarian axis through endocrine, paracrine and autocrine pathways. 
RISK FACTORS FOR OVARIAN CARCINOMA 
Fig.2. Histology of ovarian cortex Fig.3. Histology of Graffian follicle 
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Neoplasms of ovary constitutes about 30% of all cancers of female genital tract. The 
age adjusted incidence rate is highest in well developed countries.        
 The factors that risk ovarian carcinoma are three fold. 
1. Environmental 
2. Genetic 
3. Life style. 
Higher socio-economic status is included as one of the risk factors.  
About 5 - 10% of cases are familial. There is three times increased risk in individuals with 
positive family history. Majority are due to mutation in BRCA1, BRCA2 and DNA mismatch 
repair genes. Other syndromes which are associated with ovarian cancer are Lynch-II 
syndrome and Hereditary Non Polyposis Colon Cancer Syndrome(HNPCC)
16
. 
 Nulliparity, early menstruation, late menopause and ovarian inflammation are more 
commonly associated with increased risk for ovarian tumours. The above repeated traumatic 
insults might be the cause of ovarian cancers. Oral contraceptive use, multiparous women, 
pregnancy, lactation reduces the risk by reducing the ovulation process.  
 Clomiphene citrate, long term estrogen replacement therapy, obesity favour ovarian 
carcinogenesis.  Diet rich in cheese, meat increases the risk. Beverages like tea and 
vegetables  like tomato consumption reduces the risk
17
. 
CLINICAL FEATURES 
 Age > 40 Years 
 Abdominal mass 
 Abdominal pain 
 Ascites 
 In functional ovarian tumours, precocious puberty, menstrual irregularities17. 
19 
 
In high risk individuals serum biomarker assay, transvaginal ultrasound and genetic 
studies can be used as screening test
18
. 
 
SPREAD AND METASTASES 
 Modes of spread 
 Direct  
 Hematogenous   
 Lymphatic route. 
 
The metastatic sites are 
 Contralateral ovary 
 Peritoneal cavity 
 Paraaortic lymphnodes 
 Liver 
 Lung [Yolksac & Choriocarcinoma] by hematogenous spread16. 
CLASSIFICATION 
 Novak, in 1967 classified ovarian tumours as benign/malignant and cystic/solid. The 
advantage being simple. Disadvantage is that the borderline tumours fell into grey zone
19
. 
WHO (World Health Organization) in the year 1973 formulated classification based on 
histogenesis. The above classification was updated in 1999 and  2003
7,20
. 
WHO CLASSIFICATION OF TUMOURS OF THE OVARY. 
I. SURFACE EPITHELIAL – STROMAL. 
Serous tumours 
 Malignant 
 Adenocarcinoma 
20 
 
 Borderline tumour 
 Benign – cystadenoma, adenofibroma, cystadenofibroma. 
Mucinous tumours: 
 Malignant 
 Adenocarcinoma 
 Borderline tumour 
 Benign – Cystadenoma, adenofibroma, cystadenofibroma  
 Mucinous cystic tumours with pseudomyxoma peritonei 
Endometrioid tumours: 
 Malignant  
 Adenocarcinoma 
 Malignant  mixed mullerian tumour 
 Endometrial stromal sarcoma. 
 Benign – cystadenoma, adenofibroma, cystadenofibroma. 
Clear cell tumours: 
 Malignant 
 Adenocarcinoma 
 Borderline tumours 
 Benign – Cystadenoma, adenofibroma, cystadenofibroma. 
Transitional tumours 
 Malignant  
 Transitional cell carcinoma (non-Brenner type) 
 Malignant Brenner tumour 
 Borderline 
 Benign Brenner tumour 
21 
 
Squamous cell carcinoma 
Mixed epithelial tumours 
 Malignant 
 Borderline 
 Benign 
Undifferentiated and unclassified tumours: 
 Undifferentiated carcinoma 
 Adenocarcinoma, not otherwise specified. 
II. SEX CORD – STROMAL TUMOURS. 
Granulosa-stromal cell tumour 
 Granulosa cell tumour 
 Adult Granulosa cell tumour 
 Juvenile granulosa cell tumour 
 Thecoma Fibroma group 
 Thecoma, not otherwise specified. 
 Typical 
 Luteinized. 
 Fibroma 
 Cellular Fibroma 
 Fibrosarcoma 
 Stromal tumour with minor sex cord elements 
 Sclerosing stromal tumour 
 Signet-ring stromal tumour 
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Sertoli-Stromal cell tumours: 
 Sertoli Leydig cell tumour group. 
 Well differentiated 
 Of intermediate differentiation variant with heterologous elements 
 Poorly differentiated variant with heterologous element. 
 Retiform variant with heterologous elements. 
 Sertoli cell tumour 
 Stromal –Leydig cell tumour 
SEX CORD – STROMAL TUMOURS OF MIXED OR UNCLASSIFIED CELL TYPE. 
 Sex cord tumour with annular tubules  
 Gynandroblastoma 
 Sex cord stromal tumours, unclassified. 
Steriod cell tumours 
 Stromal luteoma 
 Leydig cell tumour group 
Hilus cell tumour 
Leydig cell tumour, non hilar type 
Leydig cell tumour, not otherwise specified. 
 Steroid cell tumour, not otherwise specified  
Well differentiated 
Malignant 
III. GERM CELL TUMOURS 
 Primitive Germ cell tumours 
 Dysgerminoma 
 Yolk Sac tumour 
23 
 
 Embryonal carcinoma 
 Polyembryoma 
 Non Gestational Choriocarcinoma 
 Mixed Germ cell tumour 
 Biphasic or Triphasic Teratoma 
 Immature Teratoma 
 Mature Teratoma 
 Solid 
 Cystic 
 Fetiform Teratoma. 
 Monodermal teratoma and somatic type tumours associated with dermoid cyst 
 Thyroid tumour groups 
 Struma Ovarii 
 Benign 
 Malignant 
 Carcinoid tumour 
 Neuroectodermal tumour group 
 Carcinoma group 
 Melanocytic group 
 Malignant melanoma 
 Melanocytic nevus 
 Sarcoma group 
 Sebaceous tumour group 
 Pituitary type tumour group 
 Retinal anlage tumour group. 
24 
 
Germ Cell Sex Cord – Stromal Tumour 
 Gonadoblastoma – Variant with malignant germ cell tumour. 
 Mixed germ cell – sex cord – Stromal tumour variant with malignant germ cell 
tumour. 
IV. TUMOURS OF THE RETE OVARII: 
 Adeno carcinoma 
 Adenoma 
 Cystadenoma 
 Cystadeno fibroma 
V. MISCELLANEOUS TUMOURS: 
 Small cell carcinoma hypercalcemic type 
 Small cell carcinoma, pulmonary type 
 Large cell neuroendocrine carcinoma 
 Hepatoid carcinoma 
 Primary ovarian mesothelioma 
 Wilms tumour 
 Gestational choriocarcinoma 
 Hydatidiform mole 
 Adenoid cystic carcinoma  
 Basal cell tumour 
 Ovarian Wolffian tumour 
 Paraganglioma 
 Myxoma 
 Soft tissue tumours, not specific to the ovary. 
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VI. TUMOUR LIKE CONDITIONS 
 Luteoma of pregnancy 
 Stromal hyperthecosis 
 Stromal hyperplasia.  
 Fibromatosis 
 Massive ovarian edema 
VII. LYMPHOID AND HAEMATOPOIETIC TUMOURS 
VIII. SECONDARY TUMOURS 
I. SURFACE EPITHELIAL – STROMAL TUMOURS: 
 The cell of origin is from surface epithelium, or serosa of ovary.  60% of ovarian 
neoplasm, and 80-90% of primary ovarian malignancies belong to this group. The benign 
epithelial tumours are common in middle age. The malignant epithelial tumours are common 
in perimenopausal age group
16
.  
MOLECULAR PATHOGENESIS OF SURFACE EPITHELIAL TUMOURS 
 High grade serous and Endometrioid carcinomas arise from invagination of surface 
epithelium (inclusion cyst). This is associated with P53, BRCA1 and/or BRCA2 mutations. 
Low grade serous carcinoma arise from the mutation of RAS-RAF pathway. It is also 
associated with adenoma – borderline neoplasm-carcinoma sequence. Mucinous carcinomas 
arises in the background of mutation in K-ras oncogene. Low grade Endometrioid carcinoma 
arise in the background of endometriosis and mutations in CTNNBI (gene encoding Beta 
Catenin) and PTEN
21
. Based on cell type epithelial tumours are classified as 
 Serous 
 Mucinous 
 Endometriod 
 Clear Cell 
26 
 
Based on pattern of growth 
 Cystic 
 Solid 
Based on atypia/invasiveness 
 Benign 
 Borderline 
 Malignant tumours 
A) SEROUS TUMOURS: 
Serous tumours constitute the most common surface epithelial neoplasms. As a  result of 
mullerian differentiation along the salphingeal pathway, the cells resemble that of tubal 
epithelium
7
. 
 Serous tumours constitute 30% of all ovarian tumours out of which, 70% are benign, 
5-10% borderline and 20-25% are malignant
16,22
. 
BENIGN SEROUS TUMOURS: 
 Incidence is more common in fifth decade. 
Gross: 
 Bilaterality is seen in 10-20%. Usually unilocular, filled with clear serous fluid. They 
may be cystadenomas / adenofibroma / cystadenofibromas. Cystadenomas are cystic 
neoplasm with smooth inner surface, sometimes with papillary excrescences, hence called 
papillary serous cystadenoma. Adenofibroma contain a dense  fibrous stromal component. 
Cystadenofibroma contain polypoidal excrescences embedded in a fibrous stroma.  
Microscopy: 
 Cyst and polypoidal excrescences are lined by single layer of ciliated epithelium 
similar to fallopian tube. No nuclear atypia is seen
16,22
. 
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SEROUS BORDERLINE TUMOUR: 
 Synonyms: Atypical proliferating tumour or serous tumours of low malignant 
potential. 
Gross: 
 These tumours are bilateral in 26-36% of cases. Grossly they usually present as cystic. 
The inner surface showing more friable and numerous papillary projections. 
Cystadenofibroma has white to yellow rubbery areas.   
Microscopy: 
Diagnostic features: 
(1) Atleast 10% of the areas exhibit arborising papillae (hierarchical branching) with 
epithelial stratification. 
(2) Varying degrees of mild to moderate nuclear atypia. 
(3) Absence of destructive stromal invasion.  
Serous borderline tumours are classified as 
(1) Typical (90%) 
(2) Micropapillary (10%) 
The typical type has classical branching papillary structures with epithelial tufts overlying the 
papillae. 
The micropapillary type has thin elongated papillae. These papillae are five times longer than 
they are wide. They have no stromal support. They arise directly from the papillae with thick 
fibrous stalk. 
The following features should be looked for, after the diagnosis 
(1) Surface involvement 
             There is higher risk of transformation to higher stage in this category. 
This also enables peritoneal spread. 
28 
 
(2) Stromal microinvasion  
               Microinvasive type has micropapillary structures and discohesive 
epithelial cells. They are surrounded by clear space, in the underlying normal 
tissue. This invasive foci which is measuring less than 10mm
2
 and less than 
3mm
2
 in greatest dimension is called as microinvasion. 
(3) Lymph node metastases 
          Metastases are seen in pelvic and paraaortic lymphnodes in 27% of cases.  
           (4)Peritoneal implants: 
In 30% of cases, serous borderline tumours are associated with implants in the 
peritoneum. Classified as invasive and noninvasive types.  
Invasive implants: 
(a) Haphazardly arranged glands are seen in normal tissues like omentum. 
(b) Dense fibrous reaction without inflammation are seen surrounding  the implants. 
(c) Epithelial proliferation is seen. 
(d) Nuclear features are similar to low grade serous carcinoma. 
(e) Borders are irregular. 
(f) Aneuploidy. 
These above features are absent in noninvasive implants.
57
 
Even in the presence of invasion the prognosis seems to be good.  Because they behave 
as noninvasive neoplasms.  In child bearing group, conservative surgery is performed along 
with close clinical followup.
23,24,25,57
 
MALIGNANT SEROUS CYSTADENOCARCINOMA 
 It is the most common malignant ovarian neoplasm. It constitutes about 40-50% of 
total. 
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Gross: 
 These tumours are usually large, bilateral (70%). Size ranging from microscopic foci 
to more than 20cms in diameter. They present as cystic with papillary excrescences, solid 
growth and growth on the surface due to capsular invasion. Large areas of hemorrhage and 
necrosis are also seen. 
 Well differentiated tumours have well formed papillary structures. They have 
characteristic fibrovascular core. Psammoma bodies are common in the fibrovascular stalk. 
When 75%  of the tumour shows psammoma bodies they are called psammoma carcinoma. 
They carry favourable prognosis. Moderately differentiated tumour shows crowded 
papillae without fibrovascular core. Poorly differentiated types shows no papillary pattern. 
The cells are arranged in solid sheets. 
 The papillae has to differentiated from papillae occurring in Transitional cell 
carcinoma, Endometrioid carcinoma, clear cell carcinoma. In Endometrioid carcinoma, there 
is villous structure with focal squamous metaplasia. In clear cell carcinoma, the papillae are 
lined by hob nail/clear cells. The papillae have hyalinised core. In transitional carcinoma, the 
papillae are broad and lined by transitional cells
7,6,55
.  
 Immunostaining shows CK7 positivity, CK20 negativity, WT1, P53 expression
31
. 
Hormonal markers ER𝛼, PR𝛼 showed higher expression in malignant cases. Her-2/neu was 
found to show higher expression for malignant tumours when compared to borderline
26
. 
GRADING: 
The most commonly used Silverberg’s grading system27: 
Table:1: 
Score Architecture Cytological atypia Mitotic figures/10Hpf. 
1 Glandular Mild 0-9 
2 Papillary Moderate 10-24 
3 Solid Severe >25 
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 Score 3-5 - Grade 1 
 Score 6-7 - Grade 2 
 Score 8-9 - Grade 3 
2-Tier Grading system for serous carcinoma  
 Anais Malpica et al. classifies serous tumour into low and high grade based on 
nuclear atypia and mitotic rate
52
. 
Low grade: 
1. Mild to moderate nuclear atypia and as a secondary feature. 
2. <12 mitosis/10Hpf. 
High grade: 
1. Marked nuclear atypia and as secondary feature. 
2. >12 mitosis/10Hpf and multinucleated cells. 
B) MUCINOUS TUMOURS: 
Mucinous tumours constitute 14% of all ovarian tumours. Mucinous tumours are the 
second most common ovarian tumours. About 30.8% of all surface epithelial tumours belong 
to this category.  Of these, 75% are benign, 20% are borderline, <5% are invasive 
carcinomas. 5% are bilateral.
16,28
 
BENIGN MUCINOUS TUMOURS 
Gross: 
 Usually they are large, unilateral, multilocular. The multiloculated cyst contains 
viscous mucoid material. Cystadenofibromas present as solid tumours. 
Microscopy: 
 Depending on the lining epithelium of cyst they are classified as: 
 1) Intestinal  
2) Endocervical type.  
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          Endocervical type resembles endocervical epithelium. They have ciliated columnar 
epithelium with intracellular mucin. Intestinal type epithelium consists of goblet cells, paneth 
cells exhibiting picket fence appearance. Cystadenofibromas present as mucinous glands / 
cyst distributed in dense fibrous stroma.
29 
BORDERLINE MUCINOUS TUMOURS 
 The lining epithelium is stratified not more than 3 layers. They form filiform 
intracystic papillae with minimal stromal support. Nuclear atypia and mitotic figures are 
noted. Stromal microinvasion is a feature. This consists of isolated cells/clusters. Each cluster 
is composed of 5-10 cells without stromal reaction
28,30
. 
MALIGNANT MUCINOUS OVARIAN TUMOUR 
Synonym : Mucinous cystadenocarcinoma 
Gross: 
 They are mostly unilateral. About 5% of these tumours are bilateral. If bilateral, 
nonovarian origin should be excluded. These tumours are common in 40 to 80 years of age. 
They are large and have smooth external surface. Cut surface reveals many-thick walled 
multilocular cystic spaces. The cyst contains viscous fluid. Solid areas, hemorrhagic areas 
and necrosis are not infrequent. 
Microscopy: 
 The lining epithelium is stratified with more than 4 layers. Two forms of stromal 
invasion noted as: 
        (1) Expansile  
        (2) Infiltrative.   
             In expansile form, back to back arrangement of glands are seen with no stroma in 
between. The infiltrative type shows glands, tubules, cords, cell nest haphazardly infiltrating 
the stroma
7,16
.
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Differential Diagnosis: 
Metastatic colon adenocarcinoma: 
They are mostly bilateral. Nodular growth pattern, surface involvement and 
lymphovascular invasion are commonly associated. They are CK20 positive and CK7 
negative
31
. 
MUCINOUS TUMOUR WITH PSEUDOMYXOMA PERITONEI 
 It includes mucinous ovarian neoplasm, ascites, abundant gelatinous material within 
pelvis and abdominal cavity. We must always rule out the possibility of appendiceal 
neoplasm or other gastrointestinal primary mucinous  tumours metastatic to peritoneum
31
. 
MIXED OR COLLISION TUMOUR 
     This is due to biphasic or multiphasic differentiation. Two or more epithelial elements are 
present in varying proportions. The above entity is also seen in sex cord stromal and germ 
cell tumours. Commonly benign mucinous tumours occur in association with the mature 
cystic teratoma
7,16
.  
c) ENDOMETRIOID TUMOURS: 
BENIGN ENDOMETRIOID TUMOURS 
Gross: 
 They are solid, firm, tan with numerous cyst of varying sizes. The tumours are 
ranging from 8 to 10cms in diameter. 
Microscopy: 
 Benign appearing glands/cyst are seen. These structures are lined by endometrial type 
of cells
32
. They are sometimes associated with squamous differentiation.  
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BORDERLINE ENDOMETRIOID TUMOURS: 
Gross: 
 Mostly unilateral ranging from 2-40cms in diameter.  Cut surface is grey white, tan. 
Predominantly these tumours are solid. Large tumours, may show areas of hemorrhage and 
necrosis . 
Microscopy: 
 Crowded Endometrioid glands/cyst are seen. There is cytological atypia and low 
mitotic activity is seen. But characteristically, there is no invasion into the stroma. 15-50% of 
patients have incidence of same side ovarian  endometriosis or at other extra ovarian sites
32,60
. 
ENDOMETRIOID ADENOCARCINOMA 
 Hyperestrogenic state, atypical hyperplasia within a foci of endometriosis serve as 
risk factor for Endometrioid carcinoma. This suggests the origin of tumour is directly from 
ovarian coelomic epithelium. This entity has a very good prognosis
33
. 
Gross: 
 They present as solid, cystic friable papillae or as a mural nodule. These tumours 
range from 10 - 20cms diameter.  Bilaterality  is seen in  28% of cases. 
Microscopy: 
TABLE 2: 
FIGO grading scheme for Endometrioid adeno carcinoma: 
Grading Histological feature 
Grade 1 or well differentiated Well formed glands resembling 
villoglandular carcinoma of uterine 
corpus,<5% of solid tumour growth. 
Grade 2 or moderately differentiated  More complex, glandular architecture, 
increased nuclear stratification, 6-50% solid 
tumour growth. 
Grade 3 or poorly differentiated Poorly formed glands, large sheets of cells, 
>50% solid tumour growth. 
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Squamous differentiation is seen in 30% of cases. The differential diagnosis is metastatic 
uterine endometrial carcinoma. Endometrioid carcinoma of ovarian origin may have 
associated endometriotic foci.  The secretory change, squamous metaplasia, expansile 
invasion are evident .These tumours   shows beta catenin, EMA positivity
31
. 
.
CLEAR CELL (MESONEPHROID) TUMOURS 
Clear cell carcinomas are more common in nulliparous women
7
. They constitute 5% 
of all ovarian tumours. Clear cell carcinomas are most commonly associated with pelvic and 
endometrial endometriosis
33
. 
 Clear cell tumours are classified into benign, borderline, malignant. 
Gross: 
 Thick walled unilocular cyst is seen. Numerous fleshy yellow nodules project into the  
cyst are noted. 
Microscopy: 
 They may present as solid mass, cystic or papillary. The cores of papillae exhibit 
prominent hyalinisation. The papillae are lined by one or two layers of polygonal/flattened/or 
characteristic hobnail cells. The individual cells have clear cytoplasm containing glycogen. 
The nuclear atypia is minimal
34
. 
Differential diagnosis include 
 (1) Dysgerminoma which has polygonal shaped cells, inconspicuous nucleoli, presence of 
luminal mucin and EMA positivity. 
 (2) Metastatic renal cell carcinoma should also be considered. The clear cell renal cell 
carcinoma is CD10 positive, CK7 negative and vice-versa in clear cell carcinoma of 
ovary. 
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D) BRENNER TUMOUR (TRANSITIONAL CELL TUMOUR): 
Brenner tumour accounts for 1-2% of all ovarian neoplasm. The average age of 
presentation is about 50 years.  Bilaterality is seen in 5 to 7% of the cases
29
. 
 The cell of origin is from surface epithelial cell or cyst derived from them. This is 
through the process of metaplasia. These tumours are rarely associated with mucinous 
cystadenoma and with Transitional cell tumour of bladder. 
BENIGN BRENNER TUMOUR 
Gross: 
 Predominantly these tumour are well circumscribed. Cut surface-firm, white or 
yellowish measuring about 2 to 30cms diameter. Focal areas of calcification may be seen. 6% 
of the cases are bilateral. 
Microscopy: 
 Nests of transitional epithelial cells resembling the urothelium is seen. This is 
surrounded by abundant dense fibroblastic stroma. Individual cells have oval nuclei with 
longitudinal groove resembling coffee bean. The cells have clear cytoplasm. Cystic change 
can be seen
34
. 
BORDERLINE BRENNER TUMOUR: 
Gross: 
 Large, with an average diameter 16-20cms. Cut surface shows solid and cystic 
components. 
Microscopy: 
 Branching papillae lined by transitional epithelium protruding into cystic space. 
Spindle to oval cells without mitotic activity is seen.  There is no stromal invasion. A benign  
Brenner component is always present
34
. 
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MALIGNANT BRENNER TUMOUR 
Gross: 
  They are large tumours.  Cut surface reveals predominantly solid and few cystic 
areas. 
Microscopy: 
 These neoplasm exhibits stromal invasion. This is accompanied by a benign or 
borderline Brenner component. The invasive element present as high grade transitional cell 
carcinoma
35
. 
TRANSITIONAL CELL CARCINOMA: 
They resemble transitional cell carcinoma of urinary tract in architecture. Most 
commonly seen in age group of 50 to 58 years. 
Gross: 
 Bilateral in 15% of cases. Cut surface reveals partly solid and cystic areas.  
Occasional polypoidal projections accompanied by areas of hemorrhage and necrosis is seen. 
Microscopy 
 Characteristic papillary structures lined by multilayered transitional epithelium is 
seen. The cells exhibit pleomorphism.  These tumour should not have a benign/borderline 
Brenner component
35
. 
 This type of neoplasm has got a good prognosis. The differential diagnosis of 
metastatic tumours from urinary tract should always be considered. Transitional tumours of 
urinary tract  show classically CK 20 positive, which is absent in tumours of ovarian origin
31
.  
E) MALIGNANT MIXED MULLERIAN TUMOURS 
Gross: 
         90% of these tumours are bilateral. External surface - Bosselated mass, large tumors. 
Cut surface - Partly solid and cystic. Areas of hemorrhage and necrosis are seen. 
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Microscopy: 
 It is a biphasic neoplasm. It is composed of both malignant epithelial and 
mesenchymal component. Any of the surface epithelial tumour constitute the epithelial 
component. The mesenchymal component is fibrosarcoma / leiomyosarcoma / Endometrioid 
stromal sarcoma
34
. 
F) ADENOSARCOMA 
Gross: 
 Always unilateral. Cut surface – predominantly solid. Small cysts are occasionally 
seen. 
Microscopy: 
 Biphasic tumour in which the epithelial component is benign. But the mesenchymal 
component is malignant. The cellular stroma shows periglandular cuffing pattern. The 
adenosarcoma of ovary has grave prognosis in  comparison with its uterine counterpart
31
. 
G) ENDOMETRIAL STROMAL SARCOMA: 
Gross: 
 About 70% of tumours  present  as unilateral  tumours. Predominantly the cut surface 
is solid. Cystic areas filled with mucoid and hemorrhagic fluid material may be seen. 
Microscopy: 
 50% of cases occur in association  with endometriosis.  The characterstic features of 
numerous thick walled blood vessels are seen.  The tumour cells are arranged in whorls 
around blood vessels or in diffuse pattern.  The individual cells have round to oval nuclei 
with scanty cytoplasm
31
. 
  
38 
 
H) MIXED EPITHELIAL TUMOUR 
Microscopy: 
  Varying proportions of two or more of five major cell types are seen: serous, 
endometrioid, mucinous, clear cell, and transitional types are seen
34
. 
 
I) UNDIFFERENTIATED CARCINOMA 
Microscopy: 
 They are uncommon ovarian neoplasm. They have  no differentiation. Marked  
cytolological atypia is seen. 
II. SEX CORD STROMAL TUMOURS: 
 5% of ovarian neoplasms belong to this group of functional tumours.  The cell of 
origin is from the sex cord, parenchyma or both of the embryonic gonads.  The neoplastic 
cells differentiate into either testicular (sertoli-leydig cell tumours) or ovarian type 
(Granulosa cell tumours)
16,53
.  The sensitive and specific immuno marker for sex cord stromal 
tumours are inhibin and calretinin 
31
. 
A) GRANULOSA STROMAL CELL TUMOUR: 
They constitute 1 – 2% of ovarian tumours. 70% of sex cord stromal tumours belong to this 
group of potentially malignant tumours.  The cell of origin is follicular granulosa cells.  Two 
types: 
1) Adult Granulosa cell tumour 
2) Juvenile Granulosa cell tumour 
ADULT GRANULOSA CELL TUMOUR: 
 More common in the reproductive age group.  40% of the cases are seen in the 
menopausal age group.  About 75% of the patients present with abnormal uterine bleeding 
due to hyperstrogenism. 
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Gross: 
 These  tumours have an average diameter of 12cms.  Cut surface - Yellow to greyish 
white in colour, solid and cystic areas are seen.  Cystic area filled with hemorrhagic fluid is 
seen. Areas of hemorrhage and necrosis may be seen exhibiting a variegated appearance. 
Microscopy: 
 Growth patterns of  microfollicular with characterstic Call Exner bodies, Macro 
follicular, insular, trabecular, watered silk,diffuse, solid,  sarcomatoid are seen. Recent 
studies suggest the tumour size and mitotic index has more prognostic significance than the 
pattern
34,36
. 
 The individual granulosa cells have scanty cytoplasm with longitudinal nuclear 
grooves giving rise to coffee bean appearence. A low mitotic activity and minimal to no 
cytological atypia is noted.
22
 The granulosa cells are often surrounded by fibro thecomatous 
stroma(fibroblasts, theca/leutinised cells). The morphology and inhibin positivity strongly 
suggests granulosa stromal cell tumour
31,58
. 
JUVENILE GRANULOSA CELL TUMOUR: 
  80% of these tumours are seen in adolescent girls. Often they present with complaints 
of precocious puberty. The above entity may be seen in association with olliers 
disease/mafucci’s  syndrome. 
Gross: 
 Lobulated external surface is seen. Cut surface reveals solid to cystic areas. The solid 
areas are yellow to tan. They are soft in consistency. 
Microscopy: 
 Macrofollicular pattern are more common. Neoplastic granulosa cells are having 
abundant eosinophilic vacuolated cytoplasm. There is no grooving. Numerous mitotic figures 
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are evident. They present with distant metastasis. The patients have grave prognosis when 
compared to adult granulosa type
37
. 
B)THECOMA-FIBROMA GROUP: 
a) THECOMA: 
4% of all ovarian tumours belong to this group.  They occur in post menopausal age group
38
. 
Gross: 
 They are almost and always unilateral. An average size of 5-10cms in noted. Cut 
surface - solid, grey tan to yellow areas with well defined capsule. Firm  in consistency. 
Microscopy: 
 Fasicles of bland oval to spindle shaped cells are seen. Nuclei are fusiform with 
abundant pale vacuolated lipid rich cytoplasm. Calcification is prominent. Leutinised 
thecoma cells are also evident. They contain leutin cells, in a background of fibromatous than 
thecomatous stroma. Edema and microcyst formation are commonly seen. Mitotic figures are 
not seen. 
 Special stains like oil red O demonstrates intracytoplasmic neutral fat. Silver stains 
like reticulum, stains around each tumour cell in contrast to granulosa cells in which the 
reticulin staining is around the cluster of cells
35
. 
b) FIBROMA: 
Common ovarian tumour occurring around puberty. The patients are asymptomatic.  
Fibromas are incidentally discovered during surgery. Ovarian fibroma along with ascites and 
right sided pleural effusion constitute Meig’s syndrome. In Gorlen’s syndrome they present 
bilaterally
39.40
. 
Gross: 
 Most commonly they are unilateral.  Average  size is around 6cms in diameter. Cut 
surface -  solid, white, lobulated appearance. Hard in consistency. 
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Microscopy: 
 These tumours are composed of spindle shaped cells in interlacing fascicles. They are   
also seen in storiform pattern admixed with dense collagen. The individual cells have uniform 
bland fusiform nuclei with pointed ends and scant cytoplasm. Mitosis is absent.  10% of 
tumours have uniform densely cellular and are referred to as cellular fibromas
39.40
. 
C) SCLEROSING STROMAL TUMOUR OF OVARY 
These are benign  uncommon neoplasm seen in reproductive age group. 
Gross: 
 Unilateral, well circumscribed with an average of 15cms in diameter. Cut surface 
shows solid, grey white, lobulated with specks of yellow areas. 
Microscopy: 
 Characteristic pseudolobular pattern of growth is seen. It has alternating hyper cellular 
and hypocellular areas. Hypercellular areas shows numerous thin walled blood vessels, 
similar to hemangiopericytoma like pattern. It is composed of collagen producing spindle 
cells and lipid containing round cells. The hypocellular areas is composed of edematous 
sclerotic fibrous stroma.  
 Massive Edema of ovary is an important differential diagnosis. Normal ovarian 
structures are seen admixed with edematous areas in Edema of ovary. Where as in sclerosing 
stromal tumour, the normal ovarian stroma is replaced by the neoplasm
7,16
. 
D) SERTOLI STROMAL CELL TUMOUR 
Tumour consisting of varying proportion of sertoli cells, Leydig cells and stromal 
components are seen. 
Sertoli Leydig cell group: 
These rare tumours constitute less than 0.1% of ovarian tumours
22
.   The tumours are 
more common in younger age group. The patient presents with masculinisation or 
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defeminisation features. Previously these tumours were referred as 
Arrhenoblastoma/Androblastoma.  
Gross: 
 Most commonly they are unilateral. Solid, firm with pale yellow areas admixed with 
few areas of hemorrhage and necrosis are seen.  
Microscopy: 
1. MEYER’S type I - Well differentiated tumours. 
Sertoli cells are seen in open or closed tubules. They lack significant atypia/mitotic 
activity.    
2. MEYER’S type II – Intermediate 
Composed of cords, sheets and nests of sertoli like cells separated by spindle shaped 
stromal cells. 
3. MEYERS type III - Poorly differentiated/Sarcomatoid  
They are arranged in sarcomatoid pattern with masses of spindle cells
27
. 
 20% of tumours exhibit heterologous elements. They consist of mucinous epithelium 
of gastrointestinal tract, skeletal muscle, cartilage and neuroendocrine cells. 
E) SERTOLI CELL TUMOURS  
          They are rare neoplasms. Sertoli cell tumours are more common in reproductive age 
group.  
Gross: 
Unilateral in presentation. Average size is 5 to 7cms in diameter . 
Microscopy: 
           The neoplasm is composed of sertoli cells lining the tubules or grow in nests or solid 
sheets. The individual cells are columnar, polygonal, in shape with small round to oval nuclei 
with minimal nuclear atypia. They have granular to eosinophilic cytoplasm
27
.  
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F) SEX CORD TUMOUR WITH ANNULAR TUBULES 
These tumours may occur as solid, bilateral and multifocal tumours accompanied by 
Puetz Jegher’s syndrome. They are present as solitary neoplasm without the syndrome. Half  
of the patients present with hyperestrogenism.   
Microscopy: 
 Complex annular tubules filled with eosinophilic  material are seen. Occasional 
hyaline bodies and calcification are also seen. In several tumours the above tumour merged 
with that of granulosa cell tumour
7,16
. 
G) GYNANDROBLASTOMA 
Mixture of granulosa cell tumours (estrogenic) and sertoli–Leydig cell tumours  
androgenic features are seen.  
Gross: 
Unilateral with an average size of 1 to 18cms is seen. 
Microscopy: 
         Equal proportion of sertoli leydig cell and granulosa cell tumour are seen. Tubules and 
trabeculae of well differentiated sertoli-leydig cells are seen admixed with nests and sheets of 
granulosa cells
16
. 
H) LIPID CELL (LIPOID, STEROID CELL): 
These tumours accounts for 0.5% of all ovarian neoplasm. Lipid cell tumours are seen in 
all age groups. They occur in association with defeminisation and virilisation syndromes
22
. 
Gross: 
 Unilateral, Well circumscribed. Cut surface – yellowish nodules separated by fibrous 
septa. 
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Microscopy: 
 Tumour cells are arranged in solid sheets. The individual tumour cells are large 
polyhydral with abundant eosinophilic or vacuolated cytoplasm. The cytoplasm stains 
positivity for fat  stains
27
.  25% of these tumours turn into malignancy. They are characterised 
by necrosis and hemorrhage. Nuclear atypia and mitotic activity is increased in such cases
16
. 
III. GERM CELL TUMOURS 
 30% of ovarian neoplasm come under this category. The most common neoplasm to 
occur in younger age group (< 18 years) are germ cell tumours. Malignant germ cell tumour 
(3% of germ cell tumours) are more common in much younger age group
27
.    
 Benign cystic teratoma is the commonest type. They constitute 95% of germ cell 
tumours
41
. The cell of origin is from germ cell which has undergone defective meiotic 
division
16
.  8% of the cases are composed of two or more subtypes. They are grouped as 
malignant mixed germ cell tumours. 
A) DYSGERMINOMA: 
They constitute 1% of all ovarian cancers. Bilaterality is around 10%. It is the most 
common malignant tumour in association with gonadal dysgenesis. The patients present with 
complaints of abdominal mass and pain. 
Gross: 
 Well encapsulated tumours.  The average size is 15cms diameter. Cut surface reveals  
solid, lobular configuration, tan or white in colour.  Soft in consistency. 
Microscopy: 
 The tumour cells are found in lobules/sheets of cells with thin fibrous septa separating 
them. The fibrous septa is densely infiltrated by lymphocytes. The individual tumour cells are 
polygonal cells with clear to eosinophilic cytoplasm (PAS positive). Round vesicular nucleus 
and central prominent nucleoli is seen. In 5% of cases syncytiotrophoblasts are seen
16,41
. 
45 
 
 Anaplastic dysgerminoma resembles embryonic carcinoma.  The features of 
pscudoglandular/tubular pattern, high mitotic activity, high nuclear atypia is seen
41
. 
 Immunohistochemistry markers of CD117 and PLAP (Placental Alkaline 
Phosphatase) are positive
31
. 
B) YOLK SAC TUMOUR (ENDODERMAL SINUS TUMOUR): 
20% of primitive germ cell tumours belong to this category. These tumours are common 
in younger age group. The patient present with complaints of abdominal pain and mass. 
Gross: 
 They present as unilateral mass.  The average diameter is 15cms.  Cut section reveals 
soft, grey yellow areas with large areas of hemorrhage and necrosis. Cystic areas are not 
infrequent
42
. 
Microscopy: 
 Many patterns of reticular, solid, festoon, hepatoid, pseudo papillary, polyvesicular 
vitelline are seen. The characteristic schiller duval bodies are seen in 10 to 20% of tumours. 
They are described as papillae lined by tumour cells that project into dilated cystic spaces 
giving rise to glomeruloid bodies . PAS positive eosinophilic hyaline globules are seen
42
. 
 Clear cell carcinoma should be considered in the differential diagnosis. The nuclei in 
yolk sac tumour appears primitive. The papillae of yolksac tumour lack hyalinised core
32
. 
 Yolk sac tumours are positive for cytokeratin, Alpha1Antitrypsin
31
. 
C) EMBRYONAL CARCINOMA: 
These tumours constitute 3% of germ cell tumours.  They are most common in 
younger age group. These tumours present as a component of mixed germ cell tumours. The 
patient present with features of precocious puberty, vaginal bleeding, hirsutism and 
amenorrhea. 
  
46 
 
Gross: 
 External surface is smooth.  Cut surface shows, solid, variegated areas of hemorrhage 
and necrosis
16
. 
Microscopy: 
 Large primitive appearing cells in solid sheets and nests and also forming abortive 
glandular structures are seen. Most commonly syncytiotrophoblastic giant cells are seen
43
.
 
               
Serum alpha feta protein and chorionic gonadotrophin are elevated giving false positive 
pregnancy tests
31
. 
 These tumours have resemblance with poorly differentiated adenocarcinoma or 
undifferentiated carcinoma. The latter are more common in old age/reproductive age group. 
D) POLYEMBRYOMA                      
Embryonal carcinoma with numerous embryonal bodies are termed polembryoma. 
They are composed of an embryonal disc, yolk sac and amniotic cavities
7
. 
E) CHORIOCARCINOMA: 
Primary ovarian choriocarcinoma are very rare. They usually present as metastases 
from the uterine tumours. They have better prognosis than non gestational choriocarcinoma
7
. 
Gross: 
  Pure choriocarcinoma present as solid, hemorrhagic and friable mass
7
.  
Microscopy: 
 Biphasic pattern of syncytial and cytotrophoblastic elements in necrotic and 
hemorrhagic back ground
7
. 
 Immunohistochemistry for HCG (Human Chorionic  Gonadotrophin) is positive. 
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F) TERATOMA: 
Teratoma consists of tissues representing all the three germ layers. They are classified 
as  
1. Immature teratoma 
2. Mature teratoma 
3. Monodermal teratoma7. 
1) IMMATURE TERATOMA: 
 It is a malignant entity.  It constitutes of 1% of all ovarian tumours. The average age 
of presentation is around 20 years.  The constituents have an embryonal appearance
7
. 
Gross: 
 They are mostly unilateral. Size ranges from 15 to 18cms.  Cut surface shows partly 
cystic and solid areas. Focal areas of necrosis and hemorrhage are seen
44,45
. 
Microscopy: 
 A mixture of mature and immature elements are seen. Immature elements in the form 
of  neuroepithelial tubules, rosettes, immature cartilage, fat, liver tissue, endodermal glands 
are seen. 
 The most widely used grading Norris et al., grades the immature neuroepithelial 
elements based on amount of immature neuroepithelial elements
44,45
. 
Grading of immature teratoma: 
Table 3: 
Grade Immature tissue Amount of neuroepithelial tissue 
1 + Rare, Not  >  1/LPF/Slide 
2 + + Common, Not >  3/LPF/Slide 
3 + + + Prominent > 4/LPF /Slide. 
 
 Grade 3 teratoma occasional present with glial masses, ependymal, neuroblastoma, 
medulloepithelioma like arrangements. Immature teratoma should be differentiated from 
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carcinosarcoma with  heterologous elements.  Immature teratoma is more common in 
younger age group and consists of neuroepithelial elements
7
. 
2) MATURE TERATOMA: 
 Most common benign tumour in western world is mature cystic teratoma. It accounts 
for 25% of all ovarian tumour.   90% of germ cell tumours present as mature cystic teratoma. 
More common in 20-50 years of age. Predominantly they are unilateral tumours (88%) 
45,46
. 
Gross: 
 They present as multiloculated cyst. The cysts usually contain keratin, sebum, hair 
and teeth sometimes an imperfectly formed mandible or a partial human body like 
configuration (Homunculus/fetiform teratoma) is found. The characteristic Rokitansky 
protuberances with variety of tissue types are found. Solid areas should be grossed carefully 
to rule out immature teratoma
46
. 
Microscopy: 
 A mixture of ectodermal, mesodermal, endodermal, elements are seen. They are 
composed of hair follicles, epithelium, salivary gland, thyroid and respiratory tract 
epithelium. Rarely peritoneal glial implants/peritoneal melanosis are also seen
45,46
. 
   Benign tumours include cutaneous adnexal tumours, salivary gland tumours. In post 
menopausal age group secondary malignancy can occur.  Squamous cell carcinoma is the 
most common malignant tumour arising from it. Mature cystic teratoma can occur in 
association with mucinous cystadenoma, brenner and fibrothecoma.
(49)
 
3) MONODERMAL TERATOMA: 
It consists of tissues derived from one germ cell layer. The most common to occur is  
struma ovary. Other rare entities are carcinoid tumour and neuroectodermal elements 
tumour
7,16
. 
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STRUMA OVARII: 
 The predominant component in this type is thyroid tissue. It constitutes 2 to 7% of all 
ovarian teratomas.  Malignancy is rarely encountered. If it arises, it presents as papillary 
carcinoma with typical nuclear features.  Grossly they are less than 10cms in maximum 
extension. Cut surface is solid tan with glistening surface. Microscopic examination shows 
numerous follicles filled with colloid
7,16
.  
CARCINOID TUMOUR: 
 The neuroendocrine tumours are more common in older age group. The patient 
present with menstrual irregularities and abdominal pain.   Grossly they are unilateral. Cut 
surface shows tan yellow solid areas. Microscopically, the tumour cells are arranged in 
trabecular pattern. The nucleus has salt and pepper chromatin.  
 The most common site of metastases from intestinal carcinoid is ovary.The metastatic 
carcinoid present as multiple nodules and bilateral in presentation. 
 Immunohistochemistry markers like serotonin, chromogranin are positive
7,16
. 
G) MALIGNANT MIXED GERM CELL TUMOUR: 
5 - 20% of malignant germ cell tumours belong to this category. Usually combination  
of dysgerminomas with yolk sac tumours can be seen. They are followed by immature 
teratoma, embryonal carcinoma, choriocarcinoma. The later group have grave prognosis. 
They are common in younger age group
7,16
. 
I) MIXED GERM CELL – SEX CORD STROMAL TUMOURS:   
Dysgenetic gonadoma as it is otherwise called is associated with XY gonadal 
dysgenesis. They are composed of dysgerminoma and sex cord stromal tumours composed of 
immature sertoli and granulosa cells. Most commonly they are associated with hyalinization 
and calcification. The close   differential   diagnosis is sex cord tumours with annular tubules. 
The latter lacks germ cell components
7,16
. 
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IV. TUMOURS OF RETE OVARII: 
 They are relatively uncommon tumours. They are seen in the postmenopausal women. 
The tumour is located in the ovarian hilus.  
Microscopy: 
 Cuboidal cells, nonciliated columnar cells are seen arranged in retiform spaces. They 
may present as adenoma, cystadenoma, carcinoma
7
. 
V. TUMOURS OF UNCERTAIN ORIGIN: 
A) SMALL CELL CARCINOMA: 
 They may present as 
 Hypercalcemic type  
 Pulmonary type. 
HYPERCALCEMIC TYPE: 
 It is most common form of undifferentiated carcinoma. It is most common in young 
female and are always bilateral. The tumours are always associated with hypercalcemic. The 
above feature disappears after the removal of tumour.  
 Grossly they are large, solid with huge areas of necrosis and hemorrhage. 
Microscopically, small closely packed cells with high N/C ratio are seen. Numerous mitotic 
figures are seen. Because of extra ovarian spread, the prognosis is grim
35
. 
 The pulmonary type resembles the lung tumour. They are sometimes associated with 
endometrial carcinoma
35
. Tumours are positive for keratin, EMA, NSE and rarely 
chromogranin
31
. 
B) TUMOURS OF PROBABLY  WOLFFIAN ORIGIN: 
 Also called as wolffian adnexal tumour. They are benign tumours. Grossly they are 
solid, grey white or yellow in colour.  Microscopically the epithelial cells are arranged in 
solid sheets with cystic degeneration.  They are CK7, Calretinin, Vimentin  positive
31
. 
51 
 
VI) UNCLASSIFIED TUMOURS: 
SARCOMAS: 
 Most of them are fibrosarcoma, leiomyosarcoma, endometrial sarcoma, osteosarcoma, 
chondrosarcoma, angiosarcoma, rhabdomyosarcoma. 8% of malignancy in dermoid cyst 
occur as sarcoma
32
. 
Fibrosarcoma: 
 Common in postmenopausal women. Grossly they are fleshy with areas of 
hemorrhage and necrosis. Histology shows spindle shaped cells arranged in Herringbone 
pattern.  Nuclear atypia and mitotic figures are prominent
32
. 
VII) METASTATIC TUMOURS: 
 5 – 10% of ovarian tumours come under this category. The most common primary 
tumours to metastasize are large intestine, stomach, appendix. This is followed by breast, 
uterine corpus, uterine cervix. 
 In younger girls, metastasis occur in Neuroblastoma, Rhabdomyosarcoma,  Ewing’s 
sarcoma
13,48,49
. 
Features of ovarian metastasis: 
1. Bilaterality 
2. Surface involvement 
3. Nodular pattern of growth 
4. Hilar involvement 
5. Single cell invasion 
6. Desmoplastic reaction 
7. Vascular invasion 
8. Unusual extra ovarian spread. 
The normal ovarian parenchyma is completely replaced. They appear as solid, white,  
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sometimes cystic. Multiple serosal implants is a diagnostic feature
48
.  Immunohistochemistry 
is helpful in differentiating from primary which is CK7 positive of CK20 negative
31
. 
KRUKENBERG TUMOUR: 
 The most common primary site is stomach. Grossly, they are 
symmetrically/asymmetrically enlarged.  Cut surface reveals predominantly homogenous 
with firm, white areas. Microscopically, the tumour cells are seen as isolated single cells, 
nests, cords. The individual cells have cytoplasmic vacuoles compressing hyperchromatic 
nucleus to one side. This gives a signet ring appearance. Abundant pools of mucin are seen in 
the stroma
50,51
. 
 Special stains for mucin namely PAS and alcian blue and epithelial markers are 
positive
31
.  This tumour has a grave prognosis
50
.  
PROGNOSIS OF OVARIAN TUMOURS: 
 The important factors influencing are as follows. 
1. Histological type 
2. Molecular abnormality 
3. Stage of Ovarian cancer 
4. Women’s age and general health 
5. Whether newly diagnosed/recurred16 
ESTROGEN RECEPTOR: 
 Estrogen suppresses basal and cisplatin induced apoptosis. The etiopathogenesis is by 
increasing DNA repair capacity and avoiding apoptosis
56
. This leads to uncontrolled cell 
growth and drug resistance. The mechanism of action is by up regulation of c-myc gene. 
Estrogen also regulates genes (ezrin, fibulin, cathepsin D and kallikerins) involved in motility 
and invasion of extra cellular matrix
12
. 
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PROGESTERONE RECEPTOR: 
 Progesterone promotes cell differentiation and apoptosis.Progesterone inhibits DNA 
synthesis and cell division. Many studies have shown that there is decreased risk of ovarian 
cancer with oral contraceptives and in multiparous individual. This could be due to cyclic 
progestational climate. (serum levels  are comparable to luteal phase progesterone level)
2,6
. 
                    The mechanism  of action is three fold . Firstly a connection exists between 
progesterone action and Fas/FasL signaling in normal and malignant ovarian surface 
epithelial cell death. Secondly, through decrease in membrane fluidity. Lastly, progesterone 
induces a switch from TGF-1 𝛽1 to TGF beta 2/3 expression. This correlated with increased 
apoptotic index in ovarian surface epithelium
2,11
. 
Her-2/neu RECEPTOR 
 The term neu was coined from the rat homologue of Her-2. The rats were induced to 
produce  neuroblastoma  by nitroso ethyl urea and their DNA was used for research 
purpose.
61
 
 The Her-2/neu oncogene is located on chromosome 17. Her-2/neu oncogene encodes 
a transmembrane glycoprotein tyrosine kinase. This includes four receptors-ErbB1(HER), 
ErbB2(HER-2/neu), ErbB3(HER3) and ErbB4(HER4). HER-2 expression is well documented 
in breast. It helps in assessment of prognosis (increased risk for early recurrence and 
resistance to endocrinopathy) and in the treatment of breast cancers. Targeted monoclonal 
antibody has been used a mode of treatment in breast cancers.
2,10,59
 
 Various studies have been shown that apart from breast, HER-2 over expression is 
also seen in stomach, prostate, ovary, colon and bladder. The four receptors are monomers. 
They dimerise when bound by a ligand either with same kind of receptor (homodimerisation) 
or with other receptor (heterodimerisation). 
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Receptors  : Ligands 
 HER1   : EGF, amphiregulin, TGF (Transforming  growth factor), 
     epiregulin and betacellulin. 
 
HER2   : ASGP2 forming sialomucin  complex, MUC4 and  
    phosphorylation of HER2 
 
HER3, HER4  : Hergulins, acetylcholine receptor inducing activity,  
    signals MAP( mitogen activated protein kinase path  
    way).61 
 
ROLE IN TUMORIGENESIS: 
 Activation of HER family of receptors causes activation of Ras, MAP (mitogen 
activated protein)  kinase pathway and P13K (Phosphatidylinositol-3 Kinase) pathway. The 
RAS/MAP pathway stimulates cell proliferation. The PI3K pathway inhibits proapoptotic 
proteins like Bad, GSK3𝛽, FOXO3a through phosphorylation of AKt.
10,61
 
 HER2 Over expression is being correlated to tumour size, grade, increased proportion 
of S phase cells and aneuploidy. HER2/HER3 heterodimer has a strong mitogenic effect in 
ovarian carcinoma. The combination of cytotoxic chemotherapy and EGFR/HER inhibitors 
(Trastuzumab) has a better clinical response.
10,59
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MASTER CHART 
 
S.No. HPE No. Age in 
Years 
Clinical Presentation Gross features HPE Diagnosis FIGO 
Staging 
1. G20/13 28 Mass Abdomen Unilateral, Cystic Benign Mucinous Cystadenoma I 
2. G29/13 35 Pain Abdomen Unilateral, Cystic with Papillary 
excrescences. 
Benign Serous cystadeno fibroma I 
3. G46/13 30 Mass Abdomen Unilateral, Cystic Benign Mucinous cystadenoma I 
4. G56/13 45 Mass Abdomen Unilateral, Cystic Benign mucinous cystadenoma I 
5. G58/13 45 Pain Abdomen Unilateral, Solid Fibroma I 
6. G70/13 30 Mass Abdomen Unilateral, Cystic Benign mucinous cystadenoma I 
7. G76/13 30 Mass Abdomen Unilateral, Cystic Mature cystic Teratoma I 
8. G79/13 35 Mass Abdomen Unilateral, Solid and cystic Granulosa-Theca cell Tumour I 
9. G134/13 50 Mass Abdomen Unilateral, Cystic Benign Mucinous  Cystadenoma I 
10. G143/13 19 Mass Abdomen Unilateral, Cystic with Papillary 
excrescences 
Benign papillary Serous cystadeno 
fibroma 
I 
11. G156/13 23 Mass Abdomen Unilateral, Cystic Mature cystic Teratoma I 
12. G186/13 20 Pain Abdomen Unilateral, Cystic Mature cystic Teratoma I 
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13. G260/13 35 Mass Abdomen Unilateral, Cystic Mature cystic Teratoma I 
14. G285/13 46 Mass Abdomen Unilateral, Cystic Mature cystic Teratoma I 
15. G317/13 21 Mass Abdomen Unilateral, Cystic Mullerinosis I 
16. G354/13 55 Mass Abdomen ascites. Unilateral, Solid Krukenberg Tumour II 
17. G401/13 15 Pain Abdomen Unilateral, Solid and cystic Dysgerminoma I 
18. G402/13 39 Mass Abdomen, ascites, 
Omental deposits 
Unilateral, Solid, Variegated Endometrioid Carcinoma grade-III III 
19. G405/13 40 Mass Abdomen Unilateral, Cystic Mature cystic Teratoma I 
20. G452/13 23 Pregnancy associated Unilateral, Cystic Benign mucinous cystadenoma I 
21. G478/13 24 Mass Abdomen + 
deposits 
Unilateral, Solid, Cystic, 
Variegated 
Mixed germ cell Tumour. 
Dysgerminoma and Embryonal 
carcinoma. 
III 
22. G520/13 55 Mass Abdomen  Unilateral, Cystic Benign Serous cystadenoma I 
23. G521/13 29 Mass Abdomen  Unilateral, Cystic Benign Serous cystadenoma I 
24. G542/13 48 Mass Abdomen  Unilateral, Cystic Benign Serous cystadenoma I 
25. G579/13 35 Mass Abdomen  Unilateral, Cystic Endometrioid carcinoma I 
26. G585/13 35 Mass Abdomen  Unilateral, Cystic Benign Papillary Serous 
cystadenoma 
I 
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27. G588/13 55 Mass Abdomen  Unilateral, Cystic Borderline Serous tumour I 
28. G695/13 26 Pain Abdomen  Unilateral, Cystic Mature cystic teratoma I 
29. G700/13 50 Mass Abdomen  Unilateral, Cystic Benign mucinous cystadenoma I 
30. G708/13 33 Mass Abdomen  Bilateral, Cystic with papillary 
excrescences 
Benign papillary Serous 
cystadenoma 
I 
31. G751/13 50 Pain Abdomen  Unilateral, Cystic Mature cystic teratoma I 
32. G729/13 19 Mass Abdomen  Unilateral, solid and cystic with 
papillary excrescences 
Mucinous cystadeno carcinoma I 
33. G795/13 65 Mass Abdomen ascites Bilateral, Cystic Benign Serous cystadenoma I 
34. G811/13 35 Mass Abdomen  Bilateral, Cystic Benign mucinous cystdenoma I 
35. G829/13 47 Mass Abdomen  Unilateral, Cystic Benign mucinous cystdenoma I 
36. G843/13 39 Mass Abdomen  Unilateral, Cystic Benign mucinous cystdenoma I 
37. G845/13 42 Mass Abdomen  Unilateral, Solid and  Cystic Benign Serous cystadenoma I 
38. G851/13 53 Mass Abdomen  Unilateral, Solid and cystic with 
Hemorrhagic fluid 
Fibro thecoma I 
39. G853/13 60 Mass Abdomen ascites Bilateral, cystic Benign mucinous cystadenoma I 
40. G857/13 33 Mass Abdomen  Unilateral, Cystic Benign mucinous cystadenoma I 
58 
 
41. G872/13 60 Mass Abdomen  Unilateral, Cystic Benign mucinous cystadenoma I 
42. G911/13 52 Mass Abdomen  Unilateral, Cystic Benign mucinous cystadenoma I 
43. G918/13 32 Pain Abdomen  Unilateral, Cystic Mature Cystic Teratoma I 
44. G919/13 42 Mass, pain Abdomen  Unilateral, cystic with Hemorrhagic 
material 
Twisted/congested Benign 
Mucinous cystadenoma 
I 
45. G920/13 55 Mass Abdomen  Unilateral solid variegated Endometrioid carcinoma grade III II 
46. G925/13 45 Mass Abdomen  Unilateral solid cystic Benign Serous cyst adeno fibroma I 
47. G1021/13 21 Pain Abdomen  Bilateral, cystic Bilateral mature cystic teratoma I 
48. G1049/13 50 Mass Abdomen  Unilateral, solid, cyst with papillary 
excrescences 
Endometrioid adeno carcinoma II 
49. G1061/13 65 Mass Abdomen  Unilateral cystic with papillary 
excrescences 
Borderline mucinous cystadenoma I 
50. G1084/13 40 Mass Abdomen  Unilateral solid and cystic  Mucinous cyst adeno carcinoma I 
51. G1123/13 20 Pregnancy associated Unilateral, cystic Mature Cystic Teratoma I 
52. G1186/13 45 Mass Abdomen  Unilateral, solid cystic with 
papillary excrescences 
Borderline Serous tumour I 
53. G1195/13 60 Mass Abdomen  unilateral, solid with papillary 
excrescences 
Papillary Serous cystadeno 
carcinoma 
II 
54. G18/14 50 Mass Abdomen  unilateral solid and cystic Papillary Serous cystadeno 
Carcinoma 
I 
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55. G57/14 60 Mass Abdomen ascites  Bilateral, solid and cystic Papillary Serous cystadeno 
carcinoma 
I 
56. G140/14 40 Mass Abdomen ascites Unilateral, solid Metastatic carcinomatous deposits III 
57. G153/14 45 Mass Abdomen  Unilateral cyst with hemorrhagic 
material 
Benign, congested mucinous 
cystadenoma 
I 
58. G206/14 30 Pain abdomen  Unilateral, cystic Mature cystic teratoma I 
59. G233/14 23 Mass Abdomen  Unilateral, cystic Mature Cystic Teratoma I 
60. G238/14 23 Mass Abdomen  Unilateral, solid and cystic Immature teratoma with 
gliomatosis peritonei 
III 
61. G277/14 22 Mass Abdomen  Unilateral cystic with papillary 
excrescences 
Benign papillary Serous 
cystadenoma 
I 
62. G285/14 65 Mass Abdomen  Ascites Bilateral cystic with papillary 
excrescences 
Bilateral Benign papillary Serous 
cystadenoma 
I 
63. G300/14 25 Mass Abdomen  Unilateral, cystic Benign Serous cystadenoma I 
64. G323/14 16 Pain Abdomen  Unilateral, solid Sclerosing  stromal tumour I 
65. G328/14 27 Mass Abdomen  Unilateral, cystic with papillary 
excrescences 
Benign Serous cystadeno fibroma I 
66. G333/14 21 Mass Abdomen  Unilateral cystic Mature cystic Teratoma I 
67. G335/14 17 Pain abdomen Unilateral, cystic Mature cystic Teratoma I 
68. G344/14 35 Pain Abdomen  Unilateral cystic with hemorrhagic 
fluid 
Benign Mucinous cystadenoma I 
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69. G348/14 40 Mass and Pain 
Abdomen  
Unilateral cystic Benign mucinous cystadenoma I 
70. G399/14 40 Mass Abdomen  Unilateral solid and cystic Borderline Mucinous 
Cystadenoma 
I 
71. G436/14 35 Mass Abdomen  Unilateral, solid and cystic Granulosa cell Tumour II 
72. G438/14 40 Mass Abdomen  Unilateral and cystic Mature cystic teratoma I 
73. G445/14 46 Mass Abdomen  Bilateral, solid Dysgerminoma High grade I 
74. G458/14 42 Mass and Pain 
Abdomen  
Unilateral, solid cystic with 
papillary excrescences 
Papillary Serous cystadeno 
carcinoma 
I 
75. G466/14 23 Pain Abdomen  Unilateral cystic Mature cystic Teratoma I 
76. G469/14 25 Mass Abdomen  Unilateral cystic and solid Benign Mucinous cystadenoma I 
77. G525/14 19 Mass, Pain Abdomen  Unilateral solid and cystic Mucinous cystadeno carcinoma I 
78. G530/14 50 Mass Abdomen  Unilateral cystic Benign Serous cystadenoma I 
79. G535/14 29 Mass Abdomen  Unilateral, cystic Benign Mucinous cystadenoma I 
80. G594/14 30 Mass and Pain 
Abdomen  
Unilateral cystic with hemorrhagic 
fluid 
Benign mucinous cyst adenoma I 
81. G606/14 48 Mass Abdomen  Unilateral cystic and focal solid 
areas 
Borderline mucinous cystadenoma I 
82. G610/14 60 Mass Abdomen  Unilateral cystic Benign Serous cystadenoma I 
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83. G619/14 26 Pain Abdomen  Unilateral cystic Mature cystic Teratoma I 
84. G621/14 65 Mass and Pain 
Abdomen  
Unilateral cystic with hemorrhagic Congested Benign Mucinous                
cystadenoma 
I 
85. G644/14 29 Mass Abdomen  Unilateral cystic Benign Serous cystadenoma I 
86. G676/14 24 asymptomatic Unilateral cystic Benign Serous cystadenoma I 
87. G754/14 50 Mass Abdomen  Unilateral cystic Mature cystic teratoma I 
88. G756/14 35 Mass Abdomen  Unilateral cystic Mature cystic teratoma I 
89. G771/14 60 Mass and Pain  
Abdomen  
Unilateral cystic Borderline mucinous cystadenoma I 
90. G782/14 35 Mass Abdomen  Unilateral solid and cystic Papillary Serous cystadeno 
carcinoma 
II 
91. G798/14 52 Mass Abdomen  Unilateral cystic Borderline mucinous cystadenoma I 
92. G828/14 50 Mass Abdomen; ascites  Unilateral cystic Benign mucinous cystadenoma I 
93. G879/14 37 Mass Abdomen Pain Unilateral, cystic with Hemorrhagic 
material 
Congested Benign Serous 
cystadenoma 
I 
94. G945/14 32 Mass Abdomen  Unilateral cystic with papillary 
excrescences 
Benign papillary Serous 
cystadenoma 
I 
95. G947/14 53 Mass Abdomen  ascites Unilateral cystic Benign mucinous cystadenoma I 
96. G973/14 70 Mass Abdomen  Unilateral solid Fibro thecoma I 
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97. G983/14 22 Pain Abdomen  Unilateral cystic Mature cystic Teratoma I 
98. G1015/14 44 Mass Abdomen  Unilateral cystic Benign mucinous cystadenoma I 
99. G1003/14 44 Mass Abdomen  Unilateral, cystic Mature cystic teratoma I 
100. G1069/14 42 Mass Abdomen  Unilateral cystic with papillary 
excrescences and solid 
Papillary Serous cystadeno 
carcinoma 
I 
101. G1072/14 60 Mass and Pain 
Abdomen  
Unilateral cystic Mature cystic Teratoma I 
102. G1077/14 40 Mass Abdomen ascites Unilateral solid and cystic Endometrioid adeno 
carcinomatous deposits 
III 
103. G1083/14 57 Mass Abdomen  Bilateral solid, cystic with papillary 
excrescences 
Borderline papillary Serous 
cystadeno carcinoma 
II 
104. G1086/14 27 Mass Abdomen  Unilateral cystic Benign Serous cystadenoma I 
105. G1119/14 39 Pain Abdomen  Unilateral Simple Serous cystadenoma I 
106. G1124/14 55 Mass Abdomen  Unilateral solid Fibroma I 
107. G1126/14 30 Mass Abdomen  Unilateral cystic with papillary 
excrescences 
Borderline Serous Tumour I 
108. G1140/14 39 Mass, Pain Abdomen  Unilateral solid and cystic with 
papillary excrescences. 
Benign papillary Serous 
cystadenoma 
I 
109. G7/15 26 Mass and Pain 
Abdomen  
Unilateral, cystic Mature cystic Teratoma I 
110. G15/15 65 Mass Abdomen  Unilateral, cystic Benign Serous cystadenoma I 
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111. G18/15 63 Mass Abdomen ascites Unilateral, cystic Benign mucinous cystadenoma I 
112. G34/15 26 Mass Abdomen  Unilateral, cystic with papillary 
excrescences 
Benign papillary Serous 
cystadenoma 
I 
113. G56/15 32 Mass Abdomen  Unilateral, cystic Benign mucinous cystadenoma I 
114. G72/15 24 Mass Abdomen  Bilateral, cystic Bilateral mature cystic Teratoma I 
115. G89/15 43 Mass Abdomen, chronic 
liver disease, 
splenomegaly 
Bilateral, cystic Benign mucinous cystadenoma I 
116. G99/15 70 Mass Abdomen  Bilateral, solid cystic Bilateral Benign Serous 
cystadenoma 
II 
117. G120/15 53 Mass Abdomen  Unilateral solid cystic with 
papillary projections and 
Hemorrhagic areas and necrosis 
Adult granulosa cell tumour I 
118. G137/15 60 Mass Abdomen ascites Unilocular cystic Benign mucinous cystadenoma I 
119. G143/15 45 Mass Abdomen  Unilateral cystic and solid Benign mucinous cystadeno 
carcinoma 
I 
120. G147/15 40 Mass Abdomen  Unilateral cystic Borderline mucinous tumour of 
ovary 
I 
121. G168/15 25 Mass Abdomen  Unilateral cystic and solid areas Mature cystic teratoma I 
122. G176/15 55 Mass Abdomen, ascites 
malignant cells  
Unilateral, solid with papillary 
excrescences and Hemorrhagic 
Serous adenocarcinoma II 
123. G180/15 65 Mass Abdomen  Unilateral, cystic Benign mucinous cystadenoma I 
124. G218/15 40 Mass Abdomen  Unilateral cystic with Hemorrhagic 
fluid 
Benign mucinous cystadenoma I 
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125. G310/15 30 Mass Abdomen  Unilateral cystic, solid Benign Mucinous cystadenoma I 
126. G313/15 24 Mass Abdomen  Unilateral cystic Benign mucinous cystadenoma I 
127. G322/15 50 Mass Abdomen  Unilateral cystic Benign Serous cystadenoma I 
128. G351/15 34 Mass Abdomen  Unilateral, cystic with papillary 
excrescences 
Benign papillary Serous 
cystadenoma 
I 
129. G355/15 55 Mass Abdomen ascites Unilateral, cystic and solid with 
papillary excrescences omental 
deposits 
High grade papillary Serous 
cystadeno carcinoma 
III 
130. G363/15 45 Mass Abdomen  Unilateral, cystic Benign Serous cystadenoma I 
131. G365/15 15 Mass Abdomen  Unilateral, solid and cystic Mature teratoma with Benign 
mucinous cystadenoma 
III 
132. G389/15 39 Mass Abdomen  Unilateral cystic Twisted cystic Teratoma I 
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OBSERVATION AND RESULTS 
 
 This prospective study comprises 132 ovarian neoplasms.  The cases were referred 
from Raja Mirasudhar Government Hospital (RMH), Thanjavur Medical College.  The study 
period is from January 2013 to May 2015. 
 The following table shows the total number of ovarian neoplasms among all the 
female neoplasms. 
 
I.  TOTAL NUMBER OF OVARIAN NEOPLASM IN COMPARISON WITH THE 
TOTAL FEMALE NEOPLASMS 
Table 4:   
S.NO. PERIOD 
TOTAL NO. 
OF FEMALE 
NEOPLASMS 
TOTAL NO. 
OF 
OVARIAN 
NEOPLASMS 
PERCENTAGE 
1. January 2013 – May 2013 438 19 4.3% 
2. June 2013-December 2013 761 33 4.3% 
3. January 2014 – May 2014 479 24 5.0% 
4. June 2014 – December 2014 676 32 4.7% 
5. January 2015 – May 2015 398 24 6.0% 
 Total 2755 132 4.7% 
 
 
The average incidence of ovarian neoplasm (Benign and malignant) among female is 4.7%  
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CHART 1:  COMPARISION OF OVARIAN NEOPLASMS IN RELATION TO 
FEMALE NEOPLASMS 
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II. AGE INCIDENCE: 
 
 In this study, the age occurrence of ovarian tumours were ranging from 10 to 79 
years. According to their age, the patients were divided into 7 groups (10-19 years, 20-29 
years, 30-39 Years, 40-49 years, 50-59 years, 60-69 years, 70-79 years). The following                     
table-5 shows the age incidence of ovarian neoplasms. 
AGE INCIDENCE OF OVARIAN NEOPLASMS 
  Table 5:   
S.NO. 
AGE IN 
YEARS 
TOTAL NO. OF 
CASES 
PERCENTAGE 
1. 10-19 7 5.3 % 
2. 20-29 29 21.9 % 
3. 30-39 29 21.9 % 
4. 40-49 28 21.2 % 
5. 50-59 22 16.6 % 
6. 60-69 15 11.3 % 
7. 70-79 2 1.5 % 
 Total 132  
 
 It is evident from the above table that the highest incidence is seen among the age 
group of 20-29 years and 30-39 years. After 70 years the incidence is lowest [CHART 2] 
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CHART 2:  AGE INCIDENCE OF OVARIAN NEOPLASMS 
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III. AGE INCIDENCE OF CATEGORIES OF OVARIAN NEOPLASMS: 
 The ovarian neoplasms are classified into benign, borderline and malignant as given 
in the following table-6. 
AGE INCIDENCE OF CATEGORIES OF OVARIAN NEOPLASMS 
Table 6: 
 
 
 From the above table 6, The highest incidence of benign neoplasm is seen in the age 
group of 20-29 years (27/97 cases 27.8%). The Borderline tumours are common in the age 
group of 40-49 years (4/9 cases, 44.4%). The malignant tumours are common in the age 
group 50-59 years (8/26 cases, 30.7%) [CHART 3.] 
  
S.NO. 
AGE IN 
YEARS 
BENIGN BORDERLINE MALIGNANT 
1. 10-19 4 - 3 
2. 20-29 27 - 2 
3. 30-39 24 1 4 
4. 40-49 17 4 7 
5. 50-59 12 2 8 
6. 60-69 11 2 2 
7. 70-79 2 - - 
 Total 
97 
73.4% 
9 
6.8% 
26 
19.6% 
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CHART 3:  AGE INCIDENCE OF CATEGORIES OF OVARIAN NEOPLASMS 
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FREQUENCY DISTRIBUTION OF INDIVIDUAL BENIGN TUMOURS IN 
DIFFERENT AGE GROUPS: 
Table 6 A: 
DIAGNOSIS 
AGE IN YEARS 
TOTAL 
% 
10-19  20-29  30-39  40-49  50-59  >60 
Serous 
cystadenoma 
1 6 7 2 3 5 
24 
(18.1%) 
Serous 
cystadeno 
fibroma 
1 1 1 1   4 (3%) 
Mucinous 
cystadenoma 
0 6 11 8 5 6 
36 
(27.2%) 
Fibroma    1 1  2 (1.5%) 
Mature cystic 
teratoma 
2 14 5 5 2 1 
29 
(21.9%) 
Fibro thecoma     1 1 2(1.5%) 
Total 4 27 24 17 12 13 
97 
(100%) 
 
The benign tumours are common in the age group of 20-29 years (27/97 cases). They 
constitute 27.8% of the total number of benign ovarian neoplasms. 
  
72 
 
FREQUENCY DISTRIBUTION OF INDIVIDUAL MALIGNANT TUMOURS IN 
DIFFERENT AGE GROUPS: 
Table 6 B: 
DIAGNOSIS 
AGE IN YEARS 
TOTAL 
% 
10-19  20-29  30-39  40-49  50-59  >60 
Papillary Serous 
cystadeno carcinoma 
  1 2 4 2 
9 
(34.6%) 
Mucinous cystadeno-
carcinoma 
2   2   
4 
(15.3%) 
Granulosa cell tumour   1  1  2 (7.6%) 
Dysgerminoma 1   1   2 (7.6%) 
Endometrioid carcinoma   2 1 2  5(19.2%) 
Mixed germ cell tumour  1     1 (3.8%) 
Metastatic/krukenberg’s 
tumours 
   1 1  2 (7.6%) 
Immature teratoma  1     1 (3.8%) 
Total 3 2 4 7 8 2 
26 
(100%) 
 
 From the above Table 6B, serous carcinomas are common in the age group 50-59 
years (4/9 cases, 44.4%) Mucinous tumours are also common in the same group (2/4 cases, 
50%)  tumours are common after 40 years.  In total, the malignant tumours are commonly 
seen in the postmenopausal age group of 50-59 years.  They constitute about 8/26 cases, 
30.7% 
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IV. CLINICAL EVALUATION: 
 The clinical features of the received cases were evaluated. 
CLINICAL FEATURES OF VARIOUS OVARIAN TUMOURS: 
Table 7: 
S.NO. 
CLINICAL 
FEATURES 
NO. OF 
CASES 
PERCENTAGE 
1. Mass abdomen 89 67.4% 
2. Pain abdomen 25 18.9% 
3. Pregnancy associated 2 1.5% 
4. Ascites 13 9.8% 
5. Asymptomatic 3 2.2% 
 
 Abdominal mass is the most common clinical presentation (89/132, 67.4%). 
Abdominal pain is the second most common clinical finding (25/132, 18.9%). 2 cases were 
found to be associated with pregnancy.  3 cases were asymptomatic and detected during 
abdominal ultrasonography done for other cases (CHART 4).  2 cases had positive metastatic 
deposits in the omentum.  The ascitic fluid was positive for malignant cells in 2 cases. 
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CHART 4:  PIE CHART DEPICTING THE PERCENTAGE OF SIGNS AND 
SYMPTOMS AMONG OVARIAN TUMOUR PATIENTS. 
 
 
  
Mass abdomen
Pain abdomen
Pregnancy associated
Ascites
Asymptomatic
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V. Laterality: 
 Neoplasms are subdivided as with unilateral/bilateral ovarian involvement as given 
table .8. 
DISTRIBUTION OF OVARIAN TUMOURS IN RELATION TO LATERALITY 
Table 8: 
S.NO. TUMOURS UNILATERAL PERCENTAGE BILATERAL PERCENTAGE 
1. 
Serous  
Benign  
Borderline  
Malignant 
 
24 
3 
7 
 
 
4 
 
2 
 
 Total 34 28 % 6 54.5 % 
2. 
Mucinous  
Benign  
Borderline  
Malignant 
 
34 
6 
4 
 
 
2 
 
 Total 44 36.3% 2 18.1 % 
3. Endometrioid 5 4.1 %   
4. 
Sex cord 
stromal 
8  1  
5. 
Germ cell 
tumour 
27 23 % 2 18.1 % 
6. Metastatic 1    
7. Krukenberg’s 1    
8. 
Mixed germ 
cell tumour 
1    
 Grand Total 121  11  
 
  From the above table 8, it is evident that in serous tumours 34/40 cases (85%) were 
unilateral at the time of presentation and 15% were bilateral. Among mucinous tumours 
44/46 cases (95.6%) were unilateral and 2/46 cases (4.3%) were bilateral.  
 Among germ cell tumour, 27/29 cases (93.1%) were unilateral and 6.8% were 
bilateral at the time of presentation. 
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CHART5:  DISTRIBUTION OF OVARIAN TUMOURS IN RELATION TO 
LATERALITY OF INVOLVEMENT 
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Bilaterality is seen in 11 cases. In malignant neoplasms, most common neoplasm to occur 
bilaterally is serous tumours followed by the malignant  germ cell tumours. None of the 
mucinous carcinomas were bilateral (chart -5). 
VI. GROSS MORPHOLOGY OF OVARIAN NEOPLASM: 
 The ovarian tumours were classified into the following types based on gross 
morphology as shown in the following table 9. 
GROSS MORPHOLOGY OF OVARIAN NEOPLASMS 
Table 9: 
S. NO. GROSS MORPHOLOGY 
NUMBER OF 
CASES ( %) 
1. Pure solid 10 (7.5%) 
2. Pure cystic 45 (34%) 
3. Mixed solid and cystic 22 (16.6%) 
4. Cystic with papillary excrescences 16 (12.1%) 
5. Solid with variegated appearance 9 (6.8%) 
6. Cyst with hemorrhagic fluid 5 (3.7%) 
7. Cyst with sebaceous material and hair 25 (18.9%) 
 Total 132 (100%) 
 
  Ovarian neoplasms most commonly present as pure cystic masses 45 cases  (34%). 
This is followed by cysts with sebaceous material and hair (25 cases, 18.9%) and mixed solid 
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and cystic tumours (22 cases 16.6%). The most uncommon presentation is solid with 
variegated  appearance is 9 cases 6.8% (chart -6). 
 
 
 
CHART 6:  GROSS MORPHOLOGY OF OVARIAN TUMOURS 
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VII. DISTRIBUTION OF OVARIAN NEOPLASMS ACCORDING TO 
HISTOLOGICAL CLASSIFICATION: 
Table 10: 
S.NO. CLASSIFICATION 
NUMBER OF 
CASES 
TOTAL 
CASES 
PERCENTAGE 
1. 
SURFACE EPITHELIAL 
TUMOUR  
Benign 
Borderline 
Malignant 
 
 
 
64 
9 
18 
 
 
91 
 
68.9% 
2. 
GERM CELL TUMOUR 
Benign 
Malignant 
 
29 
3 
32 24.2% 
3. 
MIXED GERM CELL 
TUMOUR 
1 1 0.75% 
4. 
SEX CORD STROMAL 
TUMOUR  
Benign 
Malignant 
 
 
4 
2 
 
6 
 
4.5% 
5. METASTATIC 2 2 1.5% 
 Total 132 132  
 
 The above table, signifies out of 132 neoplasms surface epithelial tumour is the most 
common (91 cases, 68.9%) followed by germ cell tumours (32 cases, 24.2%)  and sex cord 
stromal tumours(6 cases, 4.5%) (CHART 7)  
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CHART 7:  INCIDENCE OF HISTOLOGICAL TYPES OF OVARIAN NEOPLASMS 
IN RELATION TO TOTAL OVARIAN NEOPLASMS 
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VIII. SUB CLASSIFICATION OF SURFACE EPITHELIAL TUMOURS: 
 The Surface epithelial tumours are classified according to WHO HISTOLOGICAL 
CLASSIFICATION and is as follows in table 11.  
Table 11: 
S.NO. CLASSIFICATION 
NUMBER 
OF 
CASES 
PERCENTAGE AVERAGE 
1. 
SEROUS TUMOURS  
Benign 
Borderline 
Malignant 
 
28 
3 
9 
 
21.2% 
2.2% 
6.8% 
43.9% 
 TOTAL 40   
2. 
MUCINOUS  
Benign 
Borderline 
Malignant 
 
36 
6 
4 
 
27.2% 
4.5% 
3% 
50.5% 
 TOTAL 46   
3. 
ENDOMETRIOID 
MALIGNANT 
5 3.7% 5.4% 
 GRAND TOTAL 91   
 
 From the above table 11, in surface epithelial tumours, in our institution, mucinous 
tumours predominates (46 cases, 50.5%) followed by serous tumours (40 cases, 43.9%).                 
9 cases of serous cystodenocarcinomas and 4 cases of mucinous cystadenocarcinomas were 
reported. Also 5 cases of Endometrioid carcinomas were reported. (CHART 8). 
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CHART 8:  INCIDENCE OF HISTOLOGICAL SUB TYPES OF SURFACE 
EPITHELIAL TUMOURS 
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IX. HISTOMORPHOLOGICAL FEATURES OF BORDERLINE SURFACE 
EPITHELIAL TUMOURS: 
Table 12: 
S.NO. 
HISTOLOGICAL 
FEATURE 
NUMBER OF 
CASES 
1.Serous Borderline 
Histology 
1. Typical 
2. Micropapillary 
 
2 
1 
Laterality 
1. Unilateral 
2. Bilateral 
 
3 
0 
Surface involvement 
1. Present 
2. Absent 
 
0 
3 
Microinvasion 
1. Present 
2. Absent 
 
0 
3 
2.Mucinous Borderline 
Histology 
1. Intestinal 
2. Endocervical 
 
5 
1 
 
 The above table 12 depicts that predominantly borderline serous tumours presented 
with hierarchical branching pattern of papillae (2/3 cases, 66.6%) with all the cases being 
unilateral at presentation. None of the cases had evidence of surface involvement or 
microinvasion. The mucinous tumours were predominantly of intestinal type (5/6 cases, 
83.3%)    
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X. HISTOMORPHOLOGY OF MALIGNANT SURFACE EPITHELIAL TUMOUR: 
Table 13: 
S.NO. HISTOLOGICAL TYPE 
NUMBER OF 
CASES 
1. 
Serous Grading 
1. Low Grade 
2. High Grade 
 
3 
6 
 Total 9 
2. 
Mucinous Type of invasion 
1. Expansive 
2. Infiltrating 
 
4 
0 
 Total 4 
   
Malignant serous neoplasms were graded according to recent 2 tier system of classification. 
High grade tumours exhibited marked nuclear atypia and >12 mitosis/10Hpf. From the above 
table 13, 3/9 cases (33.3%) were low grade carcinomas and   6/9 cases (66.6%) were high 
grade carcinomas.   High grade carcinomas constitute the commonest type in the malignant 
serous tumours. All the 4 cases of mucinous carcinomas presented with expansile type of 
invasion with back to back gland arrangement and no stroma in between. 
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XI. SEX CORD STROMAL CELL TUMOURS: 
 The sex cord stromal tumours were sub classified and the incidence is as follows. 
Table 14: 
S.NO. CLASSIFICATION 
NUMBER OF 
CASES 
PERCENTAGE 
1. 
Granulosa cell tumour 
(adult type) 
2 33.3% 
2. Fibroma 2 33.3% 
3. Fibrothecoma 2 33.3% 
 Total 6  
 
 From the above table, in sex cord stromal cell tumours granulosa cell tumour, fibroma 
and fibrothecoma had the same incidence of (2/6 cases, 33.3%) (CHART 9).  All the cases 
reported as granulose cell tumour were adult type. 
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CHART 9:  INCIDENCE OF SUB TYPES OF SEX CORD STROMAL TUMOURS 
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XII. GERM CELL TUMOURS: 
 Germ cell neoplasms were subdivided and their individual type incidence is as given 
in the following table 15. 
Table 15: 
S.NO. CLASSIFICATION 
NUMBER OF 
CASES 
PERCENTAGE 
1. 
TERATOMA 
1. Benign 
2. Malignant 
 
29 
1 
 
90.9% 
2. Dysgerminoma 2 6% 
3. Mixed germ cell tumour 1 3% 
 Total 33  
 
 The above table depicts that among germ cell tumours, mature cystic teratomas 
dominates (29 cases, 90.9%) followed by dysgerminoma (2 cases 6%) and mixed germ cell 
tumour (1 case, 3%) (CHART 10).  The mixed germ cell tumour was a combination of 
dysgerminoma and embryonal carcinoma. 
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CHART 10:  INCIDENCE OF SUB TYPES OF GERM CELL TUMOURS 
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XIII. IMMUNOHISTOCHEMISTRY: 
EXPRESSION PROFILE OF ER, PR AND Her-2/neu IN MALIGNANT TUMOURS. 
 
Table 16: 
 
Sl. 
No. 
HPE 
No. 
HPE DIAGNOSIS ER PR Her-2/neu 
1 579/13 Endometrioid carcinoma Negative Negative Negative(1+) 
2 920/13 Endometrioid carcinoma Positive Positive Negative(0+) 
3 1077/14 Endometrioid carcinoma 
Strong 
Positive 
Strong 
Positive 
Negative(0+) 
4 1195/13 High grade serous carcinoma Positive Positive Negative(1+) 
5 57/14 
Bilateral High grade serous 
carcinoma 
Positive Negative Positive(3+) 
6 458/14 High grade serous carcinoma Negative Positive Positive(3+) 
7 782/14 Low grade serous carcinoma Negative Negative Negative(0+) 
8 355/14 High grade serous carcinoma Positive Positive Positive(3+) 
9 792/13 Mucinous carcinoma Negative Negative Negative(0+) 
10 1084/13 Mucinous carcinoma Negative Negative Positive(2+) 
11 525/14 Mucinous carcinoma Negative Negative Negative(1+) 
 
11 cases out of 26 malignant surface epithelial ovarian tumors were selected for 
immunohistochemistry.  ER, PR expression was evaluated in the 11 malignant surface 
epithelial ovarian cancers. 
 ER and PR expression was based on the proportion of cells in a given tumor specimen 
exhibiting distinct nuclear immune positivity as well as intensity of staining (Negative <10% 
and positive 10%) (Table 16). 
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 11malignant surface epithelial ovarian including carcinomas of different grades were 
taken for Her-2/neu analysis.  Her-2/neu grading 0 and 1+ were considered as negative and 
3+ as positive, 2+ was considered to be equivocal.  From the above Table 16, we infer ER, 
PR expression is stronger in Endometrioid (2/3cases, 66.6%) and serous (3/5 cases, 80%).  
They had negative expression in mucinous tumours.  
 Her-2/neu expression is higher in malignant tumour when compared to borderline 
tumours (Table 17).  And in histological types Her-2/neu expression is higher in high grade 
serous carcinoma when compared to low grade tumours, mucinous and Endometrioid 
carcinomas. 
XIV.  EXPRESSION PROFILE OF Her-2/neu IN BORDERLINE TUMOURS. 
Table 17: 
Sl. 
No. 
HPE No. HPE DIAGNOSIS Her-2/neu 
1 1126/14 Borderline serous tumour Negative(1+) 
2 G1061/13 Borderline mucinous tumour Negative(0+) 
3 G399/14 Borderline mucinous tumour Negative(0+) 
4 G798/14 Borderline mucinous tumour Negative(0+) 
5 G77/14 Borderline mucinous tumour Negative(0+) 
 
5 out of 9 cases were selected for immunohistochemical analysis.  The expression of Her-
2/neu in 2 types of borderline surface epithelial tumour were studied and the expression is 
tabulated as above (Table 17).  All the Borderline tumours showed negative expression of 
Her-2/neu. 
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XV. EXPRESSION ER, PR in SEROUS TUMOURS. 
Table 18: 
Type of serous 
tumour 
No. of 
cases 
ER Expression PR Expression 
High Grade 4 Positive Positive 
Low Grade 1 Negative Negative 
 
 The above Table 18 shows that the high grade serous tumour were positive for ER, 
PR receptors.  The low grade serous tumours are negative for ER, PR receptors 
XVI. EXPRESSION OF ER, PR IN MUCINOUS TUMOURS: 
 From the Table 16, it is evident that all the mucinous tumours in our study showed 
negative expression for ER and PR Receptors. 
XVII. EXPRESSION OF ER, PR IN ENDOMETRIOID TUMOURS: 
 From the Table 16, we infer that all the three Endometrioid tumours showed positive 
expression of ER and PR Receptors.  Based on four tiered scale (Level 1, <10%, Level 2,   
10-40%, Level 3, 50-70% and Level 4, >80%) of cells showing positive expression, One case 
showed Level 4, i.e., >80% expression of both ER and PR expression. 
XVIII. EXPRESSION OF Her-2/neu IN BORDERLINE AND MALIGNANT 
SURFACE EPITHELIAL OVARIAN TUMOURS: 
Table 19: 
 
S.No. Type of Tumour No. of 
cases 
Positive 
(3+) 
Equivocal 
(2+) 
Negative 
(1+, 0) 
1 Borderline Tumours 5 - - 5 
2 Serous Tumours High Grade 
5 
2  2 
3 Serous Tumours  Low Grade - 1 - 
4 Mucinous Tumours 3 - 2 1 
5 Endometrioid Tumours 3 - - 3 
92 
 
From the above table it is evident Her-2/neu expression in the borderline tumour is totally 
negative.  In malignant category 2/11 cases (18.1%) showed (3+) positive immunostaining.  
3/11 cases (27.2%) were equivocal(2+).  6/11 (54.5%) showed negative expression.  It is 
inferred from the above table Her-2/neu expression is significantly positive in malignant 
tumour,  Her-2/neu expression was associated with high grade surface epithelial ovarian 
tumours.  However, the intensity of positivity did not correlate with the type or grade of the 
tumour. 
 
CHART 11:  EXPRESSION OF Her-2/neu IN BORDERLINE AND MALIGNANT 
SURFACE EPITHELIAL OVARIAN TUMOURS 
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DISCUSSION 
 
Ovaries are common sites of non-neoplastic and neoplastic lesions.  The constant 
cyclical changes from puberty to menopause give rise to different cell types, each of which 
results in a varieties of tumours
32
. 
The diverse histopathologies in ovarian tumours reflects the different cell origins
63
.  
Recent surveillance, epidemiology and end result (SEER) calculations of lifetime risk for 
ovarian carcinoma are that, 1 in 55 women will develop ovarian cancer over their life time
62
.  
As the symptoms are vague and manifest over time ovarian cancers are difficult to detect 
until they are in advanced stage
62
. 
Identification of various histological patterns of ovarian tumours is important in 
diagnosis, prognosis and treatment of ovarian cancers.  Immunohistochemistry is now 
emerging as an important tool in diagnosis of ovarian tumours
10
.  It has been shown that 
estrogen and progesterone receptor level depends on histological grade, stage and variables 
among the tumours of same grade
56
.  Her-2/neu is amplified and overexpressed in 25 to 30% 
of human ovarian cancers.  It is associated with progression of invasive cancer, poor 
prognosis and resistance to chemotherapy
53. 
 In this study, about 14,093 surgical specimens were received over a period of                   
2 ½ years.  Of the 631 gynaecological tumours 132 ovarian neoplasms were reported.  This 
accounts for about 20.9% of all gynaecological tumours reported in this study.  Total number 
of malignancies reported during the study period is 1089 and total ovarian malignancies is 26. 
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I. INCIDENCE 
 
In our study, the ovarian cancer constitute 2.1% of all female malignancies [Table 20, 
Chart 12]. 
INCIDENCE OF MALIGNANT OVARIAN TUMOURS IN RELATION TO TOTAL 
MALIGNANCIES IN FEMALES. 
TABLE 20:   
Sl. 
No. 
PERIOD 
TOTAL No. OF 
MALIGNANCIES
IN FEMALES 
TOTAL No. 
OF 
MALIGNANT 
OVARIAN 
NEOPLASMS 
PERCENTAGE 
1 Jan. 13 to May 13 274 4 0.3% 
2 June 13 to Dec. 13 244 7 0.6% 
3 Jan. 14 to May 14 192 6 0.5% 
4 June 14 to Dec. 14. 269 4 0.3% 
5 Jan. 15 to May 15 110 5 0.4% 
 Total 1089 26 2.1% 
 
 In our study period spanning for a period of 2 ½ years, a total of 1089 female 
malignancies were reported.  Out of which 26 ovarian malignancies were reported.  This 
accounts for about 2.1%.  The above is depicted in Chart 12. 
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CHART 12:  INCIDENCE OF MALIGNANT OVARIAN TUMOURS IN RELATION 
TO TOTAL FEMALE MALIGNANCY 
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II. INCIDENCE OF HISTOLOGICAL TYPES OF MALIGNANT TUMOURS IN 
RELATION TO TOTAL OVARIAN MALIGNANCIES. 
TABLE 21: 
HISTOLOGICAL TYPE 
No. OF 
CASES 
% OF 
TOTAL 
MALIGNANT 
OVARIAN 
TUMOUR(26) 
% INCIDENCE 
OF TOTAL 
OVARIAN 
TUMOURS 
(132) 
Papillary serous cystadenocarcinoma 9 34.6% 6.8% 
Mucinous cystadenocarcinoma 4 15.3% 3.0% 
Granulosa cell tumour 2 7.6% 1.5% 
Dysgerminoma 2 7.6% 1.5% 
Endometrioid carcinoma 5 19.2% 3.7% 
Mixed germ cell tumour 1 3.8% 0.7% 
Metastatic adeno/krukenberg’s 2 7.6% 1.5% 
Immature teratoma 1 3.8% 0.7% 
 
 From the above Table 21 it is inferred that of total 26 malignant ovarian tumours most 
common was papillary serous cystadenocarcinoma.  The above equates to 34.6% (9/26) 
followed by Endometrioid carcinoma accounting for 19.2% (5/26).  The least common type is 
mixed germ cell tumour and immature teratoma (Chart 13). 
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CHART 13:  INCIDENCE OF MALIGNANT OVARIAN TUMOURS 
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III. INCIDENCE OF OVARIAN CARCINOMA IN RELATION TO OTHER 
STUDIES: 
TABLE-22: 
 
S.NO. 
 PLACE OF STUDY INCIDENCE 
1. Kooning’s et al.,, United States 15.8% 
2. Santhosh Kumar mondal et al., [2011] in Eastern India 9.5% 
3. 
Grand Medical College and Sir J.J. group of Hospitals., 
Mumbai. 
27.8% 
4. Adayar Cancer Institute, Chennai. 5.1% 
5. Dindigul Ambilikkai Cancer registry 3.3% 
6. Present study. 2.1% 
 
 From the above table it is evident, the incidence rate is highest (15.8%) in developed 
countries. In India, the incidence rate is highest in Mumbai (27.8%) and least is Dindigul 
Ambilikkai Cancer Registry (3.3%). Our study is undertaken in a semiurban area with an 
incidence rate of 2.1%.  This is midway between a rural and urban area [Chart-14] 
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CHART 14:  INCIDENCE OF OVARIAN CARCINOMA IN RELATION TO OTHER 
STUDIES 
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IV. INCIDENCE OF OVARIAN MALIGNANCIES  IN COMPARISON WITH 
OTHER FEMALE GENITAL  TRACT MALIGNANCIES: 
TABLE-23. 
 
S.NO. 
 
SITE 
NO. OF FEMALE 
GENITAL TRACT 
MALIGNANCIES 
 
PERCENTAGE 
 
1. Cervix 578 91.1% 
2. Ovary 26 4.1% 
3. Endometrium 22 3.4% 
4. Vulva 6 0.9% 
5. Vagina 2 0.3% 
6. Fallopian tube  - - 
 Total 634  
 
 From the above table, we infer that ovarian cancers are the second most common 
(4.1% ) malignancy among all female genital tract malignancies. Uterine cervix (91.1%) is 
the most common site to be involved and the least common site is vagina (Chart 15). 
 The age specific incidence of ovarian neoplasm ranges from 20-70 years. In America, 
Koonings et al., reported 94% of benign tumours were common in the age group of 20-29 
years and 92% of the malignant tumours were common after sixth decade.
22
   In our study, 
27.8% of Benign neoplasm were common in the age group of 20-29 years and the malignant 
tumour were common in 5
th
 decade. This study correlates well with studies conducted by 
Santhosh Kumar mondal et al.,
63
 Kayastha et al.,
64
. In comparison with western countries, 
our study proves, an earlier age of onset of malignant tumours. 
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CHART 15:  INCIDENCE OF OVARIAN MALIGNANCIES IN RELATION TO 
FEMALE GENITAL TRACT MALIGNANCIES 
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V. COMPARISON OF PERCENTAGE OF BENIGN, BORDERLINE AND 
MALIGNANT TUMOURS WITH OTHER STUDIES: 
TABLE-24:   
 
S.NO. 
 
AUTHOR 
KOONINGS et al., 
BENIGN BORDER LINE MALIGNANT 
1. Koonings et al., 75.4% 3.6% 20.9% 
2. Pilli et al., 76% 2.8% 21.2% 
3. 
Santhosh Kumar 
Mondal et al., 
63.1% 7.3% 22.9% 
4. M.Yogambal et al., 78.6% 0.7% 20.65% 
5. Present study 73.4% 6.8% 19.6% 
 
 The results of our study is comparable with Koonings et al.,
22
, Pilli et al.,
66
, and 
M.Yogambal et al.,
65
. Comparison of incidence of benign, borderline and malignant tumours 
with other in our  studies  is depicted in table 24 (Chart-16). 
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CHART 16:  INCIDENCE OF OVARIAN TUMOURS IN RELATION TO OTHER 
STUDIES 
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VI. COMPARISON OF INCIDENCE OF HISTOLOGICAL TYPES OF OVARIAN 
TUMOURS WITH OTHER STUDIES. 
TABLE-25: 
 
S.NO
. 
 
AUTHOR 
PLACE 
OF 
STUDY 
SURFACE 
EPITHELIA
L TUMOUR 
GERM CELL 
TUMOUR 
SEX CORD 
STROMAL 
TUMOUR 
METASTASES 
1. 
Pillai.G                
et al., 
India 70.9% 21.2% 6.7% 0.7% 
2. Samina et al., Pakistan 68.5% 23% 8.6% 2.6% 
3. 
Yohambal et 
al., 
Chennai 60% 13% 10% 3% 
4. Present study Thanjavur 68.9% 24.2% 4.5% 1.5% 
 
 In our study, surface epithelial tumours constitute the majority of ovarian tumour 
(68.9%) followed by germ cell tumours (24.2%) and sex cord stromal tumours (4.5%). The 
above data coincides with Samina et al.,
67
 in which surface epithelial tumour constituted 
68.5% and germ cell tumour (23%). The above table compares the incidence of histological 
types of ovarian tumours with other studies Table-25 (Chart-17). 
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CHART 17:  COMPARING THE INCIDENCE OF HISTOLOGICAL TYPES OF 
OVARIAN TUMOURS IN RELATION TO OTHER STUDIES 
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VII. COMPARISON OF INCIDENCE OF HISTOLOGICAL SUB TYPES OF 
SURFACE EPITHELIAL TUMOURS IN RELATION TO OTHER STUDIES. 
TABLE-26: 
 
S.NO
. 
 
AUTHOR 
PLACE OF 
STUDY 
SEROUS MUCINOUS ENDOMETRIOID 
1. Samina et al., Pakistan 66% 18.7% 2.2% 
2. Pillai et al., India 42.9% 41.6% 3.2% 
3. Sylvia et al., Pondicherry 53.33% 28% 6% 
4. Present study Thanjavur 43.9% 50.5% 5.4% 
 
 Among all surface epithelial ovarian tumours, mucinous tumours (41.6%) constitute 
the commonest followed by serous (43.9%) and Endometrioid (5.4%). This is not in 
concordance with the other three studies mentioned above. The above table 26 compares the 
incidence of histological types of surface epithelial tumours in relation to other studies      
(Chart-18) 
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CHART 18:  COMPARING THE INCIDENCE OF HISTOLOGICAL SUB TYPES OF 
SURFACE EPITHILIAL TUMOURS IN RELATION TO OTHER STUDIES 
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VIII. COMPARISON OF SEROUS TUMOURS INCIDENCE OTHER STUDIES: 
TABLE-27: 
 
S.NO. 
 
AUTHOR 
PLACE OF 
STUDY 
BENIGN BORDERLINE MALIGNANT 
1. Misra et al., 
Uttar 
Pradesh 
75.2% 2.3% 21.1% 
2. Samina et al., Pakistan 38% 2% 4.9% 
3. 
Hiremath et 
al., 
Pondicherry 46% 8% 13.5% 
4. Present study Thanjavur 70% 7.5% 22.5% 
 
 According Jefferey et al.,
34
, serous borderline  tumors presented as commonest type  
among the borderline tumours. In contrast, our study depicts a higher incidence of mucinous 
borderline tumours (66.6%) when compared to serous borderline tumours (33.3%). 
 Neeraj lalwani et al.,
30
 in his study states 1/3
rd
 of serous borderline tumours were 
bilateral and were associated with peritoneal implants . In  contrast in our  study all the serous 
borderline tumours were unilateral and none had positive peritoneal implants. 
 According to Anais malpica et al.,
52
, ovarian serous tumours are divided into  low 
grade and high grade according to recent two tier grading system. The above phenomena is 
based primarily on nuclear atypia and the secondary feature , mitotic rate.  
 According to Jefferay SD et al.,
34
 surface epithelial carcinomas are divided into Type 
I and II based on different pathways of tumorigenesis  
 According to Robert J.Kurman the low grade neoplasm arise through Stepwise 
process from borderline tumours. These include low grade serous, mucinous, Endometrioid, 
malignant Brenner, clear cell Carcinomas 
21
.  Type II tumours arising denovo are aggressive 
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neoplasms. Type II tumours present at advanced stages. These include high grade serous, 
malignant mixed mullerian tumour, undifferentiated carcinoma.
52,55
 
 The incidence of Benign Borderline and malignant tumours in our study is compared 
with other studies (Table-27) and is represented in Chart-19. 
 
 
 
 
 
CHART 19:  COMPARING THE INCIDENCE OF SEROUS TUMOURS IN 
RELATION TO OTHER STUDIES 
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IX. COMPARISON OF MUCINOUS TUMOURS INCIDENCE WITH OTHER 
STUDIES  
TABLE-28 
 
S.NO. 
 
AUTHOR 
PLACE OF 
STUDY 
BENIGN BORDERLINE MALIGNANT 
1. 
Koonings et 
al., 
USA 74.5% 10% 15% 
2. 
Hiremath et 
al., 
Pondicherry 76% 6.5% 17.5% 
3. R Jha et al., Nepal 75% 10% 15% 
4. Present study Thanjavur 78.2% 13% 8.6% 
 
 In our study mucinous tumour is the most common surface epithelial tumour of which 
78.2% were benign, 13% were borderline and 8.6% were malignant. This is in contrast to the 
studies of Koonings et al.,
22
  Hiremath et al.,
62
 Misra et al.,
68
  which stated that serous 
tumours constituted the commonest type of surface epithelial tumours. The above (Table 28) 
compares the incidence of mucinous tumour in our institution with respect to other studies 
and is also depicted in the (Chart-20) 
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CHART 20:  COMPARING THE INCIDENCE OF MUCINOUS TUMOURS IN 
RELATION TO OTHER STUDIES 
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 According to Jaime et al.,
60
 endometriosis is associated with high incidence of 
Endometrioid, clear cell carcinomas, mucinous and serous carcinoma. In contrast  in our 
study none of Endometrioid carcinoma (5/132) cases were associated with endometriosis. 
 In our study 33 cases of germ cell tumours were reported. This constitute about  
24.2% of all ovarian neoplasms. In germ cell tumours, mature cystic teratoma is the 
commonest group constitutes 90.9%, followed by dysgerminoma 6% and mixed germ cell 
tumour 3%. This is in concordance with studies of Kwok et al.,
43 
and Norries HJ et al.,
44
 .  
According to the above authors, malignancy in germ cell tumours is associated with post 
menopausal age group. This is in contrast to our study where one case which was reported as 
immature teratoma, was reported in younger age group. 
 According to P.Singh et al.,
47
 the commonest tumour associated with pregnancy is 
dermoid cyst. In our study ,2 cases were reported which were associated with pregnancy. One 
was associated with dermoid cyst, the other case was reported in association with mucinous 
cyst adenoma. One case of mixed germ cell tumour was reported. This tumour was a 
combination of Dysgerminoma and Embryonal carcinoma. 
 In our study, a total of 6 cases of sex cord stromal tumours were reported . This 
accounts for about 4.5% of all ovarian tumours.  Granulosa cell tumour, fibroma, 
fibrothecoma had the same incidence of 33.3%. The above data had no coincidence with any 
of the studies.  
 According to Lawrence et al.,
69
 95% of granulosa cell tumours are unilateral. All the 
2 cases in our study were unilateral and none were associated with endometrial hyperplasia. 
 According to masaki mandai et al.,
50
 5-10% of neoplasm arise from metastases. 
Ovarian metastases have some common features. Some of them are bilaterality, surface 
involvement, extensive extra ovarian spread, desmoplastic reaction, vascular invasion and 
126 
 
unusual clinical history
16,50
. In our study one case of Krukenberg’s and one case of metastatic 
adeno carcinomatous deposit was reported. Both were unilateral in presentation. 
 The krukenberg’s tumour was characterised by the presence of mucin filled, signet 
ring tumour cells within cellular stroma. 
X. COMPARISON OF INCIDENCE OF ER/PR EXPRESSION IN SURFACE 
EPITHELIAL TUMOURS. IN RELATION TO OTHER STUDIES: 
TABLE-29: 
 
S.NO. 
 
AUTHOR ER EXPRESSION PR EXPRESSION 
1. Sylvia et al., 33% 63% 
2. 
Estrid V.S. Hogdall et 
al., 
36% 20% 
3. Present study 36.3% 45.4% 
 
 In our study, ER expression is positive in 4/11 cases ((36.3%) cases, PR expression is 
positive in 5/11 (45.4%) which coincides  with study of Sylvia et al.,
26
. ER,PR has strong 
expression in Endometrioid (2/3,66.6%) and high grade serous tumours (3/5 cases 80%) 
which is similar to findings of Agarwal et al.,
70
, Damia et al.,
77
. This is in contrast to 
Buchynska et al.,
72
 who stated that ER expression is lower in high grade tumour. The above 
features suggests possible mitogenic role of ER in ovarian tumours and high PR positivity in 
conjunction with ER expression is indicative of estrogen regulated disease. The above is 
depicted in (Chart-21). 
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CHART 21:  INCIDENCE OF ER, PR EXPRESSION IN SURFACE EPITHELIAL 
TUMOURS IN RELATION TO OTHER STUDIES 
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XI. COMPARISON OF EXPRESSION OF Her-2/neu  IN BORDERLINE AND 
MALIGNANT SURFACE EPITHELIAL TUMOURS. 
TABLE-30: 
 
S.NO. 
 
AUTHOR BORDERLINE MALIGNANT 
1. Sapna Go et al., - 48.6% 
2. Sylvia et al., 1% 21% 
3. Present study - 36.3% 
 
 From the above table, we infer that HER-2  expression is negative in borderline 
tumours and shows positivity  in high grade malignant tumours mostly commonly in high 
grade serous tumours (3/5 cases, 60%). This is in concordance with Sylvia et al.,
26
 and Sapna 
Go et al.,
74
. 
 Borderline tumours occur in younger women less than 40 years of age. To preserve 
fertility, conservative surgery is the treatment of choice. These patients should be monitored 
routinely for CA-125 serum levels and ultrasound examinations. The clinical course lies in 
between the benign and malignant tumours. Evidence suggests they are known to metastasize 
within the peritoneal cavity
28
.    
 In mucinous borderline tumours the identification of stromal invasion is difficult. This 
is because of gross and microscopic multiloculation. But, atypical nuclei and stratification of 
more than 3 layers suggests well differentiated mucinous carcinoma even when there is no 
stromal invasion
28
. 
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 In our study, Her-2/neu was positive (3/5 cases 60%) in serous tumours and 1/3 
(33.3%) cases of mucinous tumours. This is in concordance with studies of sapna Go et al.,
74
 
and is depicted in the following Table-31 and Chart-22. 
Table 31: 
 
S.NO. 
 
AUTHOR 
EXPRESSION OF Her-2/neu IN 
SEROUS TUMOURS MUCINOUS TUMOURS 
1. Sapna Goel et al., 72% 66.7% 
2. Manisha sarkar et al., 50% - 
3. Present study 60% 33.3% 
 
 
 
CHART 22:  COMPARING THE EXPRESSION OF Her-2/neu  IN RELATION TO 
OTHER STUDIES 
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 The scoring system of Her-2/neu, showed variations, in individual authors study 
which is depicted in the following Table32. 
Table 32: 
 
S.NO. 
 
AUTHOR 
SCORING OF Her-2/neu IN SURFACE EPITHELIAL 
TUMOURS 
3+ 1+,2+ 
1. Manisha Sarkar et al., 35% 20% 
2. Marvann et al., 6% 32% 
3. Present study 27% 36.3% 
 
 In our study, the intensity of positivity did not correlate with age, size and grade of the 
tumours. This is in concordance with Sapna Goel et al.,
74
 and Sylvia et al.,
26
 (Chart-22) 
 From the above data, Her-2/neu expression is found to be positive only in malignant 
tumours.  This suggests their carcinogenic role and helps in distinguishing borderline and 
malignant tumours. 
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CONCLUSION: 
 A total of 132 cases were evaluated in concordance with clinical history, 
histopathological and immunohistochemistry and the following conclusions were arrived at.  
1. The incidence of ovarian neoplasms among all female neoplasms is 4.7% 
2. The incidence of ovarian malignancies among all female malignancies is 2.1% 
3. Ovarian malignancy (4.1%) is the second most common malignancy in female genital 
tract  next to cervical malignancy. 
4. In age groups, ovarian neoplasms are commoner in 2nd decade and in 4th decade. 
5. The ratio of benign and malignant ovarian neoplasm is 3:1. 
6. Predominantly they presented as unilateral tumours (90%) than bilateral (10%). 
7. Grossly, benign tumours presented, as cystic neoplasms and the malignant tumours 
presented as solid and cystic or purely solid. 
8. Regarding Histological type, surface epithelial tumours (68.9%) are the most common 
neoplasm among which mucinous cystadenoma is the commonest. 
9.  Positive expression of ER,PR (steroid receptors) in surface epithelial malignancies 
proves the mitogenic role of estrogen  in ovarian tumours. PR expression may be related 
to estrogenic regulation. The expression of steroid receptors paves way for antihormonal 
therapy. 
10. Her-2 neu was expressed only in malignant tumours. This suggests their carcinogenic 
role. This also helps in differentiating borderline and malignant tumours. 
This study is an institution based one with a small sample size of 132 cases. The     
results may not actually reflect the original age distribution and histological pattern of 
ovarian tumours in Indian population. The epidemiological data of developed countries in 
many aspects differ from the developing nations. The differences about hormone receptors 
expression by different authors may be due to various parameters like case selection, method 
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of immunohistochemistry and sample size and different grading systems. This should be 
standardized  to identify reliable prognostic markers in the clinical trial of hormone therapy. 
A multicentric, large population based study with facility of follow up will be needed to 
prove the prognostic significance of anti Her-2/neu therapy in surface epithelial carcinomas. 
Thus a panel of markers will be helpful in prognostication of ovarian tumour and 
development of targeted therapy. This study will serve as a reference for future studies. 
Continued research studies in future would accomplish an effective therapy for ovarian 
cancer. 
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APPENDIX I 
HAEMATOXYLIN AND EOSIN STAIN 
Preparation of solution : 
HARRIS HAEMATOXYLIN 
Distilled water-1000ml 
Ammonium alum-100g 
Absolute ethyl alcohol-50ml 
Mercuric oxide-2.5g 
100g  of ammonium alum dissolved in 1000ml of distilled water by heating and shaking at 
60.c. Add solution of 5g of haematoxylin in 50ml of ethylalcohol and bring rapidly to boil. 
when it begins to boil, remove from flame and add 2.5 g of mercuric oxide. Mix by swirling 
gently. 
EOSIN STAIN 
Eosin Y- 1 g. 
Distilled water-20ml. 
95% ethanol-80ml 
Glacial acetic acid-0.2ml 
Dissolve 1 gm of eosin Y in 20ml of water, add 80 ml of 95% ethyl alcohol and 0.2 ml of 
glacial acetic acid. 
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Procedure : 
1. Bring the sections to water 
2. Dip in Harris haematoxylin for 15 minutes. 
3. Rinse in tap water. 
4. Differentiate in 1% acid alcohol-3-4 quick dips. 
5. Wash in tap water briefly. 
6. Dip in ammonia water or saturated lithium carbonate until the sections are blue. 
7. Wash in running tap water for 10-20 minutes. 
8. Stain with eosin for 15 seconds to 2 minutes depending on the age of the eosin and the 
depth of counter stain. 
9. Rinse in tap water. 
10. Dip in 95% alcohol 
11. 3 changes in absolute alcohol. 
12. Xylene – 2 changes. 
13. Mount in DPX mountant. 
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APPENDIX II 
IMMUNOHISTOCHEMISTRY 
PREPARATION OF SOLUTIONS: 
Tris buffer saline (TBS): 0.005M 
Distilled water-10 litres 
Sodium chloride- 80gms 
Tris (hydroxymethylamine)-6.05g 
1 M HCl-44 ml. 
Final pH is adjusted to 7.6 with either 1 M HCl or 0.2 M Tris solution. 
CITRATE  BUFFER SOLUTION 
Trisodium citrate-2.94 gm 
1 N HCl-5ml 
Distilled water-1000 ml 
Final pH is adjusted to 6.0 with 1 N HCl. 
Preparation of gelatine coated slides: 
Chrome alum-0.05gm 
Gelatine-0.3 gm 
Distilled water-100 ml. 
Chrome alum is added to distilled water and then heated to 60.c.gelatin is added 
slowly to the heated distilled water. Glass slides are then dipped in this solution and 
dried overnight. 
Antigen retrieval: 
The slides are placed in citrate buffer in the coplin jar and capped. The jar is then 
heated in a 750 W domestic microwave oven for 15 minutes. 
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Procedure : 
1. Dewax the section in xylene (1/2 hr, 2 changes) and bring section to distilled 
water. 
2. Antigen retrievel using TBS by microwave oven heating 
3. Cool to room temperature in running tap water for 20 minutes. 
4. Bring the section to TBS for 5 minutes. 
5. Drain and wipe off excess TBS around sections 
6. Incubate in endogenous peroxidase blocking agent for  15-20 minutes. 
7. Gently wash the slide in TBS for 5 minutes. 
8. Wipe off excess fluid and incubate in power block for 15-20 minutes 
9. Blot and dry excess power block. 
10. Incubate in primary antibody for 60 minutes. 
11. Repeat steps 4 and 5. 
12. Incubate in superenhancer for 30 minutes. 
13. Repeat steps 4 and 5. 
14. Incubate in secondary antibody for 30 minutes. 
15. Repeat steps 4 and 5 
16. Incubate in DAB(Diamino Benzidine) substrate buffer for 2-10 minutes 
17. Wash in distilled water counter stain with haematoxylin, clear in xylene and 
mount with DPX. 
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APPENDIX III 
Tumor, Node, Metastasis (TNM) Staging Scheme for ovarian carcinomas: 
PRIMARY TUMOR (T) 
TNM Category International Federation of Gynaecology and Obstetrics-Obstetrics-FIGO 
TX   Primary tumor cannot be assessed 
T0   No evidence of primary tumor 
T1 I   Tumor limited to ovaries (one or both) 
T1a      1A  Tumor limited to one ovary; capsule intact, no tumor on 
   surface or no malignant cells in ascites/ peritoneal washings. 
T1b       IB Tumor limited to both ovaries, capsule intact, no tumor on surface or 
no malignant cells in ascites/ peritoneal washings. 
T1c       IC Tumor limited to one or both ovaries with any of the following: 
capsule ruptured, tumor on ovarian surface, malignant cells in ascites 
or peritoneal washings. 
T2 II Tumor involves one or both ovaries with pelvic extension and/or 
implants 
T2a       IIA Extension and/or implants on uterus and / or tubes. No malignant cells 
in ascites or peritoneal washings 
T2b       IIB Extension to and/or peritoneal implants to other pelvic tissues. No 
malignant cells in ascites or peritoneal washings. 
T2c       II C Pelvic extension and/or implants with malignant cells in peritoneal 
washings or ascites. 
T3 and/or N1 III Tumor involves one or both ovaries with microscopically confirmed 
peritoneal metastasis outside the pelvis. 
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T3a       IIIA Microscopic   peritoneal metastasis beyond the pelvis (no macroscopic 
tumor). 
T3b      III B Macroscopic  peritoneal  metastasis beyond the pelvis < 2 cm in 
greatest dimension. 
T3c       III C Macroscopic  peritoneal metastasis beyond the pelvis > 2 cm in 
greatest dimension. 
M1         IV Distant metastasis (excludes peritoneal metastasis) 
REGIONAL LYMPHNODE (N): 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymphnode  metastasis. 
N1 Regional lymphnode metastasis. 
DISTANT METASTASIS (M): 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis. 
M1 Distant metastasis (excludes peritoneal metastasis). 
STAGE GROUPING: 
Stage IA: T1a N0 M0 
Stage 1B: T1b N0 M0 
Stage 1C: T1c N0 M0 
Stage IIA: T2a N0 M0 
Stage IIB: T2b N0 M0 
Stage IIC: T2c N0 M0 
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Stage IIIA: T3a N0 M0 
Stage IIIB: T3b N0 M0 
Stage IIIC: T3c N0 M0 
                   Any T N1 M0 
Stage IV : Any T Any N M1. 
  
140 
 
BIBLIOGRAPHY 
 
1. Endocrine signalling in ovarian surface epithelium and cancer peter CK leung and Jung 
Hyechin, Human reproduction update Vol.13 NO2 pg 143-16 
 
2. Contribution of 1HC in prognostic assessment of epithelial ovarian carcinoma – review 
article ACTA MEDICA 2006 49(3) pg 161-165 
 
3. Ovarian Carcinoma by Race and ethnicity 
 
4. Changing Trends in incidence of ovarian carcinoma the Indian scenario-Asian pacific 
journal of Carcinoma prevention  Vol.10, 2009 
 
5. Jeffrey T, Quirk et al., risk factors for invasive epithelial ovarian carcinoma by 
histological subtype 2004 vol.3 
 
6. Harmonal biology of epithelial ovarian carcinoma with hypothesis concerning the role of 
androgens and progesterone-journal of natural Cancer institute Vol.90.No.23. Dec 2, 
1998 
7. Langley F.A., Fox.H., Ovarian Tumours classification histogenesis etiology.  Obstetrical 
and Gynaecological Pathology.  Fox H and Wells M (Eds) Newyork: Churchil 
Livingstone; 1995; 727-969. 
 
8. Lee G et al., FNAC in the diagnosis and classification of recurrent and metastatic gynaec 
malignancy 1988 vol.29, 375-378 
 
9. Kurman R.J. et al., molecular pathogenesis & extra ovarian origin of epithelial ovarian 
cancer shifts the paradigm.  Human pathology 2011, vol.42, 918-931 
 
10. Prognostic biomarkers in ovarian Carcinoma Jie Haung, Wei Her and Anil K Sood. 
Cancer Biomark, PMC 2014 Aug.26 
 
11. ER, PR and epithelial ovarian carcinoma reproduction biology and Endocrinology shuk-
Mei-Ho; 7 oct 2003 
 
12. Prognostic value of ER,PR tumour expression in Danish ovarian cancer patients from 
the ‘MALOVA ovarian cancer study oncology report 18, 1051-1059, 2007 
 
13. Saadia tariq et al., Study of ovarian tumours in young girls.  Professional Medical 
Journal 2011; vol.18, 41-45 
 
14. Sadler T.W., Urogenital System In: Langmans Medical Embryology (8th Edition) 
Philadelphi : Lippincotts Williams and Wilkins; 2000; 304-345. 
 
15. Inderbir Singh et. al., Human embryology, 7th Edition, 2008. 
 
16. Rosai J. Ovary In. Ackerman’s Surgical Pathology Vol2 (9th Edition).  St. Louis: Mosby 
2004 1649-1736. 
 
17. Caninstra S.A. 2004, Cancer of Ovary, N Eng. J Med., 351; 2519-2529 
141 
 
 
18. Tuma R.S. Origin of ovarian cancer, may have implications for screening, Journal of the 
national cancer institute, Vol102, No.1, pp 11-132, 2010 
 
19. Novak E.R, Gynaecological and obstetrical pathology.  6th edition, Philadelphia 
Saunders; 1967 
 
20. Tavassoli F.A. Devillee P (Eds): In diagnostic pathology and molecular genetics; World 
health organisation classification of tumours of breast and female genital tract 
 
21. Robert J. Kurman, Le-Ming Shin, Pathogenesis of Ovarian Cancer; Lessons from 
Morphology and Molecular Biology and their Clinical Interpretations.  Int. J 
Gyneacopathol, 2008, April, (27(2) 151-160. 
 
22. Koonings PP, Campbell K, Mishell DR, Relative frequency of primary ovarian 
neoplasm; 10 year review.  obstet gynaecol 1989;74:921-26 
 
23. S.V. Kane, R. Bhardwaj, H.B. Tonga Onkar, Borderline epithelial tumours of the ovary.  
A retrospective analysis of 31 cases. Indian J Cancer 1999:16:18 – 31 
 
24. Marta Ann Crispens. borderline ovarian tumours; A review of recent literature curr opin 
obstet Gynaecology 2993;15:39-43 
 
25. Dar et al., Clinical and pathological study of ovarian serous borderline tumours.  Cancer 
research on 17-08-2011 
 
26. Mary T. Sylvia et al., The expression of immunohistochemical markers estrogen 
receptor, progesterone receptor, Her-2/neu, P53 and Ki67, in epithelial ovarian 
tumours and its correlation with clinicopathologic variable; Indian Journal of 
Pathology and Microbiology – 55(1), Jan-March 2012 
 
27. Steven G. Silverberg.  Principles and practice of surgical pathology and cytopathology, 
Fourth edition, Vol.2 
 
28. Brigette M Ronnett et al., Mucinous borderline ovarian tumours, points of general 
agreement and persistency controversies; Journal of Human Pathology 2004,               
446-458 
29. Maheswari V, Tyagi SP, Saxsena K, Tyagi N, Sharma R, Aziz M, et al., Surface 
epithelial tumours of ovary.  Indian Journal of Pathology  and Microbiology, 1994, 37. 
75-85 
 
30. Neeraj Lalcoani et al., Current update on borderline ovarian tumours, AJR:194, 
Feb.2010; 330-335 
 
31. Me cluggage, Recent advances in immunohistochemistry in the diagnosis of ovarian 
pathology. Jclin Path 2000;53;327-334 
 
32. Stacey E Mills, Stenbergs Diagnostic Surgical Pathology, Vol.II 5th edition 
 
 
142 
 
33. Vigano P., Somighana E., Chiodol, Molomech and biological plausibility underlying the 
malignant transformation of endometriosis: A critical analysis.  Human reproduction 
update, 2008, Vol622, pp79-87 
 
34. Jeffray SD, Russel P, Robert KJ, Surface epithelial tumours.  In Robert Kurman J. 
Blausteins pathology of female genital tract, 5th Edition 2002: 791-881 
 
35. Stanley J. Robbins – Robboys pathology of female genital tract, 2nd Edition 
 
36. Stuart G.C.,E; Dawson, L.M., Update on granulosa cell tumours of the ovary curr 
opinion ostet gynecol 2003, V;15, p33-7 
 
37. Tanaka Y, Sasaki Y, Nishihira H, Izavsa T, Nishi T: Ovarian juvenile granulosa cell 
tumour associated with Maiffucc’s syndrome.  Am J Chin Pathol 1992; 97;             
523-527 
 
38. Gaffney EF, Majmadar B.  Ultrastructure and immunohistochemical localisation of 
estradiol of   thecomas.  Hum Pathol 1984, 15: 153-160 
 
39. Irving et al., cellular fibroma of ovary: A study of 75 cases including mitotically active 
fibroma.  American Journal of surgical pathology 2006, August 30(8)     928-938 
 
40. Aparna Ragesh et al.,  Fibroma of ovary presenting as meigs syndrome.  A case report – 
NUJHS Vol.2, No.3, Sep. 2012 
 
41. Jacob S, Lalitha K, Gopalakrishnan K, et al., Malignant ovarian tumours – A profile: J 
obstet Gynecol Ind 1993;43:413-7 
 
42. Irfan Cicin et al., Yolk sac tumours of ovary evaluation of clinicopathological features 
and prognostic features.  European Journal of Obstetrics and Gynaecology, February 
2009 
 
43. KKM Kwok et al., Malignant mixed germ cell tumour of ovary in a 10 year old girl.  
JHK Coll. Radiology 2008;11;92-95 
 
44. Norris HJ, Zirkin HJ, Beason WL: Immature (malignant teratoma) of the ovary –                                
A clinical & pathological studies of 58 cases, 1976: 37; 2359-2372 
 
45. Min J et al., Clinical characteristics of ovarian teratoma – American Journal of 
Obstetrics and gynaecology 2001, 205; 32 
 
46. Robert J. Kurman.  Blaustein’s pathology of female genital tract, 5th edition, Page 
No:758-768 
 
47. Sing et al., Malignancy associated with benign cystic teratomas of the ovary, Scng. Med. 
Journal 1988, Vol29;30-34 
 
48. Sung-jong Lee et al., Clinical characteristics of metastatic tumours to ovaries.  Journal 
Korean Medical Science 2009, 24, 114-119 
 
143 
 
49. Adriana Diongi et al., ovarian metastatic from Colorectal carcinoma, American Journal 
of Clinical Pathology 2000, 114, Page No.111-122 
 
50. Masaki Mandai et al., Krukenberg tumours, CME Journal of gynaecologic oncology 
2004, Vol.9, 112-114 
 
51. Lee KR, et al.,  The distinction between primary and metastatic mucinous Carcinoma of 
ovary; gross and histological in 50 cases.  American Journal of Surgical Pathology 
2003, 27; 281-292 
 
52. Anais Malpaica et al., Grading of ovarian serous carcinoma using two tier grading 
system, American Journal of Surgical Pathology, Vol.28, Number 4, April 2004 
 
53. Roth LM, Recent advances in the pathology and classification of ovarian sex cord 
stromal tumours.  Int. J. Gynecopathol, V25, pp199-215, 2006 
 
54. Dos santos Lisa, MOK Evelyn, Alexia la sonos, Kay Park, Soslow Robert A, Carol 
Aghajanain and co: Squamous cell carcinoma arising in mature cystic teratoma of the 
ovary – A case series and review of the literature.  Gynaecologic oncology 2007, 105: 
321-24 
 
55. Halperin R et al., Clinical and molecular comparison between borderline serous ovarian 
tumours and advanced serous papillary ovarian carcinoma.  European Journal of 
gynaecologic oncology 2001, 22(4), 292-296 
 
56. Potential role of estrogen receptor β as a tumour suppressor of epithelial ovarian cancer 
– Carine Bossard, Muril Busson.  PLOS one 7(9) 
 
57. Dar et al., Clinical and pathological study of ovarian serous borderline tumours cancer 
research on 17-08-2011 
 
58. Adhikari et al., Granulosa cell tumour of ovary,  Clinicopathological study of six cases.  
Journal of pathology of Nepal 2011 Vol 196-99 
 
59. Her-2 status in ovarian carcinoma as a multicenter GINECO study of 320 patients.  
PLOS one Nov.2007, issue 11 
 
60. Jaime et al., Clinicopathological characteristics of ovarian carcinoma and associated 
with endometriosis.  archives of Gynaecology and obstetrics 2011 vol.28, no.2, page 
no.479-483 
 
61. Thomas Holbro, Gianluca civenni . et al., The Erb β receptors and their role in Cancer 
progression, Experimental cell research 284, 2003 99-110. 
 
62. Hiremath P.B. et al., clinical profile and pathology of ovarian tumour. International 
journal of biological and medical of biological and medical research. 2012, 3:1743-
1746.  
 
 
 
144 
 
63. Santhosh Kumar Mondal, Ranjana, Suprio Roy Chowdry. Histological pattern and 
clinical evaluation of 957 ovarian neoplasm: A 10 year study in a tertiary hospital of 
Eastern India Indian J cancer 2011, 433-437. 
 
64. Kayastha study of ovarian tumours in Nepal medical college teaching hospital. Nepal 
med coll J.2009;11, 200-202. 
 
65. M.Yogambal et al., ovarian tumours-Incidence and distribution in a tertiary referral 
centre in south India 10SR Journal of Dental and medical Sciences VOL 13 Pg74-80. 
 
66. Pillai GS, Suneeta KP, Dhaded AV, Venni VV ovarian tumours, a study of 282 cases               
J Indian med ASSOC: 2002 423-424. 
 
67. Samina  Zaman et al., A retrospective study of ovarian tumours and tumour like lesions. 
Journal Ayub med coll. Abottabad 2010 Vol 22. 
 
68. Mishra RK, Sharma SP, Gupta U, Gauri R pattern of ovarian neoplasm in eastern UP.                
J Obstet Gynecol India 1991; 41(2); 242-246. 
 
69. Lawrence M Roth et al., Recent advances in the pathology and classification of ovarian 
sex cord stromal tumours . International journal of gynacopathology . 
 
70. Agarwal N, Rao DL, Murgeshan K, Verma U mittal S,  Buckshee K. Clinical evaluation 
of steroid receptors in ovarian neoplasms. Int J gynecol obstet 1987;   145-9. 
 
71. Damiao RD, Oshima CT; Stavale JN, Goncalves. WJ, Analysis of the expression of 
ER,PR and chicken oval albumin upstream promoter transcription factor-1 in ovarian 
cancers. 
 
72. Buchynska LG, lurchenko NP, Expression of ER, PR receptors as prognostic factors in 
serous ovarian  cancers. Exp oncol 2009; 31, 48-51. 
 
73. Sapna Goel et al.,-A comparison study of HER-2/neu oncogene in Benign and malignant 
ovarian tumours. International Journal of scientific study July 2014 vol 2 pg.50-54. 
 
 
 
 
 
 
 
 
